var title_f18_23_18800="Workup of acute diarrhea";
var content_f18_23_18800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Evaluation of acute diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 581px; background-image: url(data:image/gif;base64,R0lGODlh3gFFAtUAAP///wAAAIiIiLu7u0RERCIiIt3d3ZmZmWZmZjMzMxEREe7u7szMzFVVVXd3d6qqqgAz/0Rp/4ig/7vJ/8/Pzz8/P9/f35+fnyJO/93k/2aF/5mt/19fX39/fw8PD+/v7zNc/xFB/+7x/7+/v6q7/8zW/3eS/1V3/wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADeAUUCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6Chop8BpaanqKmqq6ytrq+wsbKztLW2t6mjun8Bu75Lvb/CdsHDxgDFx8psycu7zc7RZNDSoNTV2FzX2Zvb3N9U3uCW4uPmTOWKDAEN50Tp7vHvd+umDEcP7AAKAQsA+e2MrAsIiJ+/O/DkyUuYZkEABU0MLhkoSCJChRiB4XEIEYCDAAT4tRvYwJQDivxKjdQ3RICpAg8AHEgJcWapmgVUAlhAwJQA/54+8yVIANJlAAEAGPQEaUAo0QQLSpZycDGjVSMM0XAU8hEpPwYo+yVlKSTnAIpGXBLgaEAIWyHrEgBAEODARwRD7g7JRwBAzwMGAhQAUEDBggMBEPD1e3Sf2KpXIyPb+JBrY6Jg9Umk+NHUA7RCHiwNIJeuTtPsjJpkkPMh2NYKGAAEUPIBx3qmEszu6vggMcmSs57Z6vFygMzt+LUdqJZ2gM9kHZ8lPWSBcrdfqRvRa1mxvtpbC7cNrY/3dcjAMwovg/s4b8wUjZ5kt4CoAqLQCQIw+hS3AgH+IXVAa0dJxZSBBDT13XNbKWVKA7s1Jh966Sm0XoV9XIjhMRpumP9Hhx7+AmKIdYxI4igmnhhHiiqSMoYAfWkxQCkDVEEAUujUaMSMadyIB4stdpIVYqbgtQSMTSC5RAI42tikEgHoWASPSiippBU+QmFljF8AGWQ3UQyoJZdVkomEAlJSkSUwaQ5BZRJXZrGmE3GG4eWXmQw52BAIBESAA0Qmtl9fBSAVmAGBIhBYKYoSJSifpRRggKNUweiSAS4ZYSBSRhXAwEz+CCAXaaUcAMAABA7qUqKLJobkAPwoYCoBjhp5xKaB1SimpXUV2SoCr8Y6a61V3InnJUOegsCMBqwznkz9IFkoAIcOgdgCSjaAlwGxvVNjAyOhKUABOmZKxLht3cj/QLcOtFOAqe8iw+lg/53ay7hpXrvlPgIaRkBfzB6Brl8C5CrTYPgSoW+MSNYL6r/2PhuFscdWomcRNzqA1wGOBoApoYZ6zLEpH5d1iqlDREkYygQcUGcRCBh5Y6CCDfrAnioPWC2PSo5cSsmDVouMAT4KDbPMBeeMcIw+e7yl0B4X7XE4FWdzscIKoEkYVfmUTABelxbAtdNy0WZrESqDO9YAV5rbUgELLFDouvdUdx+OSvO7370xiv0P2UI0zKm/IbfVAJnjxj1tXX4tXdbYmJYt+H6EUzt1vVBQXLUkyRZZFsOROg1wKURhGnqz/DRKsrfUUjpoS83U99C0qhnp/4BhQuRNJFGv7y2Yx+u6CrCwBFveltbV2Uc76Y77nhPqwp9KvNSo++aE5ptDgn0gc6Ih2hsOPHl99tJs/0c+1i9jPvmLrM9+Fu6/f0j88hdbP4dYqMyEATm5bUcC2+rfFuL0puu1KQw++lMS6Hc/QYxIf0LoHldGZycdQdAJHJtgFwiYlQtKEEoHRIKPrBPCyTRQGA8sYREagJQCduGCUYCJEFi4QTK5MEdWgGESsqQxJDDwhLxAAmqGxajWmSJNPiJVXQKFGGgVcVykc1RMCNAaKj6kLa3xFGoMtpS1zMg+dRNCYPwRKANIBSp9iqADJvXEG03tXIUhzQJ4xMYAUP+ljnfsGBKRokSUuWUpCtgif+4xyOL9oyNYAaKIloAAuUCMWYfL3R7ltZ/B+KiA+pJUYJCCgL5ADDE1mtYQ/Ka/KCWuPgKYUY2+RgRUDcFHovIHk5jlLG1RKzYJSwvc5JbKXqhtXQP4JZoiiYxJSmhPQpiRb1S2jnt0splz8SSOAuNDRfriGgJIiSULF69iEiGJutqmvWTSMaCpDEmXDMaNFoAavJRyADEL3LKCEU83IdNHqBFUxvBCoLq8LHAx+hqPutkygg4IZR7kYziL8JF65e1U79qTK7NEzSP80Jp7oEZgYuIAcR7qlwn1ppjSubW/mbNG6GyhOgVwLQAAEBn/MSnmKQtFpXqK8TGwhArWtGbLlvRlHWlCErcOwCOQBnMlR13bNxV6sCM46zljucfhoBnJLD0AkWjDqC6usZQCeBR4OSGKMRdK0k6JTpKvIynB6lgAvJiGi6XwIj3PRpiYZslAKCtAjOp41jqpph10dB0ekxLWkD40mZ57ayELyUO6pkyrKNJFBrOQABUCgoTVhGwoLqqHl45CgZnVrItE+wbOknYOpj2tCVULJtauIbWubQNsSTvb2KoBF7jNrW53y9ve+vYWtg3uFWor3OI2grjGTS4ikKvc5g6Cuc6Nrh+gK93qfsi62PWFBSiQOyFQwALZDa8nPhCAClwgABeo/0AAPiDe9m6CA6jggHvniwkKoIK79M0vJdRbigro97+SOG8pLgDgAj/CAwHwgIEXzIgOBKADDI4wIiwQAPBK+MKEGAGGN8zhDnv4w8r4rYhHTOIS5wLEw6BuilG84hOqmMUrAuKLYVxaGdP4mja+8VZHcUM6zFjHr9UCAxyVAD9OocdR2NcCa4RkOfwYyGlIUQKosh/HQqHJT/inRZn84ydD+QxSJlMn1TijnChAKpWKI1SyyBiQzPF3Z56KExPzq1e1pklDJFW3UFUqZAwoZqYgoqCmZZ2YDvfLmxWyaQjAgEMdSpWE6UsTZ9rLwO1ylirTK7QUFi2G9QVzaOPyKv/xIqtDIkM/c3HkSj41GDHBD9HW8EIjCdZDKpU1oPMUQj0FkOvi8ahpQIOR0VhXU0WhwmCUi5Qh60LCImvBy7Aeg5RRNmZU7Xml4xSqrJRZScVV2te98FvXRAVQvWElJsXeh5FVtlGPiLNr+0kAVg8dbSFpoTOkGU8CYmRrlfpOH7KzZFzfHEF/mxV6wBpeKZ5kmibOBS98rpn+uirwhbulMc+ut73BgNkjmWkQ3YNV+nKocU5ozgFl8zgiujdlbZS8tQ2E9stfmOOZIwsJL/3gjjirwzXwD+OthAe5LWpzTFBjsjqfkjiohOWJDaDpR6CSlp/ggI8jtncYa9IHZV7/9FcbQYaGXELToT6FKJFd6VugYdS9saabEb3rFjPCGCNILEIr4AER59ulciO3SPEIVg8x1bjCOnKTCeYeUcpiHcHmxlatOVLBCnwlCd9KYZXRnqZ4XcQPwMSdHCeRcKcENFwZwdEhqtX0Mji5iLBRpvfCYYZBl3WMfARSPj0YtuQWA3J5U7wHY3Kgkn2phwB7noivXjz7tKmuGnbCHJDrobfflO5ZuGYDZmrJh8toiBoMZr3xrCs7Ajs9Z/Zg9NNlMXJQqaSeoO8DrZvGyx3RnrQzvrXqZ3NafVajzzm547Rw8dYR9ZIpSjJrDsF9/sAjAxh7fWMqxCQELfVS5ecP/z1VbqnmeQj4OguILQ1IBBvYPQPIN+r2TVTmeWH0WPwXCdQAdtTjeTiyOyIoPb9zAAH3d8SjJPGCPGLkKG1VTAHHV0ADeDlBg0RRKApXajhoZIBXat0Dg5rHZkSyfMg0DymoPUcwWVGHO2TwPZmwdVVohUfgWUbQclYxdKD3hcdVc2jYPmq4hokAfaPlhooAh55Ah3K4QG14h4VgYnzYh35oC3r4PnYYiJo1iISoVYZ4iNaUiIqYh40Ia4z4iOyzXd0FAN8liUBGXuaFXurFXpioY/B1CvL1iTpmX6eAX6R4Y/xVXqkIZAKGXq0IZAimYLGoYw4GYbV4YxRmYblIY/8a1ovAGIzCCGV/WIzGeIzImIzKuIyl8CWR2IvPOD/DSAjRaAjVGIvXSI3T+FzOuI0O1I1tkH1iMHVZcHZlN0lZZnXwY1lD8HPiUwfu2AXdk43cSARA8RDvuAXlh3VgQI5YYI5o1QQhlY6Zw44pY5AeoY5eQDQ0EgVV9wXzCI55UTYHoJAyEoNh4I9XAJBOt1RjUpAG1ARqtwXcggDpUwA6JQUjyQURGSTNgHISs3iBcQ/KtHkEQ0WLF2rZRytFlJM2cRQ/mY9FMHhyNGZ+ET5q5g9dxE5+skauE1hP1BpDUQoxESWOV3jI4CizwimkQ0hd+W/tx2W+MWQqIUhfWUj/UUKW0WEtJHNGTKlGOckrEuMWCKBXKHNVhWeU7/JFrlFGS6lKvdIaplE2bukcFkeFLRI7CMAPzpZ7scFKtlRqzEcrhrMt3XKQO2l6jqkUJQhaRdAaRiZ812cAh0Jpp4RpzeIxwnR7ZnNLu6dJjTFmENRuFjU4BANNz/R5uYlSfRFPNhVvrIObjKabfWFKKSdCnKJTqFlLlvma7OgSCEMTaaKX3DdqxXOavYQ3nASbbKOcAjAwLZmYSXAt5wcrjnZsWXJ+3rKT3HQyA0AUjPaeIHGCSJCEtMZ4ERQzRsJr9xl+fsF9hHEySnJOxXkW2+dDXDZ/roYqCxpR5WaebyRG/yXhbA/FoBI1GFY5obT3SpykLP15flPHTnZpgR1FBNSZbvi0n73mTQMKT8pST+GpIs2gdqBSgWWhaSPIoTNkZcXEnsZjo0NQgUAqMB1obYTUF0NFaTKRNd+CVEV1Ni36OlFigIzzgGhVouryeVOlpcMpVQGVAKj2NjAVVbTRpWXqTZZGOdaTU9YzEzwFpT91QSVpPXTjEcc5LtIDoA93nbtEU8VAoJIUS2/jbfsnnnDkd0b0M9CiIxEnTokaoT0qgtQDhF2lfp7CBPbpUqCjE222Fp+zg3IGlT8TpUhidvwwhPvQJi+xSlxJGl7pqnNBOjGSD22iGqaiWGf5laYUaP+0IT53xauRBqqj2hd1cn814zsJcII/J296Gk9Z8pd/yptohVeyowCihIKGugkdp5FlwIX9aJFZYB1YWQWVxQj0+I2cgHI+RQncYmjZKqPeGAjnKq/xCgjzaq8vhJBgwJFUwK2B4K9ooHM9hwUAK33vumQhyQVqeTY9gXZkULDjFLFPABZI8JBZALFlILD6aoEqB5KZI5EglLBbYBdkGqvNwK9TALEoCxdDoaogoQUYSwYa+wUxOzEgOwRqqS0ks1i6ehaOoh/jwpgUSDpvNiMb6hD3gHL+Yy9ghKyNlje8krP1aQogYzxyyXdZJKppRnlFwDHOtq72+HnE9wA5GZf/kqZ/XZsSSOGWaXSUZnsphQkpfcaTgsJXqzRwZfYQaJZWxJIo/MiXl5pFiHd7TQslNxs4x8lMxCmcMnWcg8pLgoppQqlA6OJwbqIyXyOcBrMrq2eGTgWo01KaaGs5vnd1qymaSIAYTfIyTMI/B7Aural7mwkjHDOXr1SCkdtLqWlGzZkwuXsEs0YAq0ZMpnRpvRRKkiappseWHBh0UqUftgdprGS4LnkEZkQaplKhDgpRxXS9X2uBX5NPK2qPntVPyVBsDbq5zeO9G9pUrxO64Kd+deF6/tkymaowQxGaH9cuilEo7nIyIMoP7jol8MkA4vuhAhojB9wS2rRsByVJ/7vWa7dWPIcCbBxkaeNXRPu4p9R7sEOJoTFBVWYaSRCEp+uapCkpsW4yfJzmsDEjwn7WOPxYSWqKs1zqF2ADflSagUWFVPebFC2bFh+3LoPRAPViozYqKqCkVJoCLCm8pG96LgzzxL3nbsXTNUZFaf2WbdJkPOIGflfnUggQge7EmnsKVG/nwf92q6Oaq7C6q30GO5yKVze0wJsWdLqWw7DKH81jq70KM7JqL6QShKfKbEWotb0Df0lBn7mzOh6IFPAGhECIJIiBfhgTKVIFrDg6yVyCV98UKRXXGKxBKnfrZlvso6V5OhxEOqTJg2Wcblp2r0F0BjWrBuLqCeUKCv8rm8tnCK+0DK6HuLId7Mv1miGHW8w/csxRho47JJTtyMKHYJ5lCMxeIMvTBQcD2cyMVIKyZnE0s7FJRs0hWwlJJ8S3pcxokM3IqQRzdwVtRZ91GUauJgYOYbvnUMsGS8xnYJNp4xPOg3h/NjO447lYKLhgCVFxfC5DgSMOkS/+3I4qo0ydcg8GXRdthW91wyRTC6s3QkXrCWd7C0WkIUWEUThEqVNL+W+795VWBBJm1hZ9dJOS4joiPZVQtU6AhNCMoxri7HLVmwaSCRHFmy4Awi7twBI+Ei+KzJ+fOR8x0TDLN2+X6zEzoracdoK+iQB12i5EQEoBAVUmmo+MS5n/OplpyVtJpBmbVSu6BjB72InGZDpmn5RpfGSbZH26sMlJ0sRtQhDUaIzPVPPTZ2CsuQKjLHUKGKojsEQAbncuRpLBieFqwnZsQ7nQcBEM8HaQlVfBiA3ZZWxpiXEQwHKFF9p8knTKMQi6Jt2AETzPDQpuBedNzJKeLGPJLNrFDZU0AMyxYIbOYQDNxettdarZxWMdGo2/ECgWAATD0NzVWl0EktkPDWAqoIIxYJoUlwktsvTZHogyGp1NY3nDErTBE3zbOLw37+cyfQog+gPDagVOVnxXPhwjgLomzsLCMBxlvr2vbBYl1bo8GqzYOHI76TN3bOVWkQIwbNbVlM1n/0h4ExtKq4HjK67sTdZBtJ5nOOLDWO9I3gZH39I6I4NsnymtGivN0f5WPKtqSINFqnvtOY1qsvt2zoJNCB+EANx8KzzKBYBdbresPeC8h/u9B+hjvc0dQaw8Bu36jwpgz44wsGlY48h8XVI+5RRCItbciFnOB1t+iF2uB18eiGH+I8xY5mZ+5mie5sho5WYw5myODW7+5uUj5wwW53SuPnduYHae58aw53yOQn/+X34e6M9A6Faj5oiO5obe5vIz6C/n6GC+6GUA6VQu6WJA6cls6Zfe6Jq+6YLY6cWCW+mRW6COh4EdHPlc6ogpBZju6WWn6mnM6qOe6rC+WrIOHP8a0up6zhVlA00agevnwhLXGuu1bkK85FI5HlqRkQzZVGrD3svFXgyw0lEL4JNWbetXweyFYhgAnqyrHu0mmjbN6ZmViOqDGkhzQ5zfXuvna37uWcDlvuxw5DssVdrYWuy2TiVD2prYbhXabjLs7aXrDuvtLqxRg8nxnu3zDi2t6u33Du6nLu8RD/GvDuwTz+60rh4Zr+q5PusXT/AbbyEhD+qkjuuiju/j8+konz+cvvL0xj66jmgx72Mu//LkM/PE2PI1//EVg/NAhumJHvTNuI1Aj+dEH1kh5o1Fn/RHLwo+P/DQiPT40/SJxvTTOOiUaEKXqAtZHwxbD4yDron/55Ve67ULYs+JZR+Mjh6KpjCKu8D2peD2YA8KpmgKqKgLdV8Kdx/1oLCK/iUMfn/1ofCKBCYMhC/4oTCLx6D4iA8Kt3gMj9/4n7CLx0D5kv8Jv3gMmT+MT7/z1uj5wgVdQn+MmTP6JCbzJRKHAml0qE/zdfixN/dloq/66MD6sp/6r/8EYd75cI77G5fy5ND6qFUmps2Guk/8UP7LNq9js482w1r8ZkC/NHf8zn9WyW8GgM371dD8oZZWzjwGwrz61N/9pRrkNNvTys78vs86KZWVfWaTGB2UrXRnSyh4XiVHWXsv9w8VDgcECARAEAgUGAuCUQFwPgNP6VQapQYG/0QCADsIJAIKBmBQMB4ADmOAoTaOoYcConxOrxkGcMChNbDJAhbqAg6UmK6oFBcZGx0fISMlJykrLS8xp6wyOROvsgS2CAS4SAUKABTQHpoCHp4I+qgUSJ1oAQ4UFk4NFlS9nIB5fQ8OrIQYxNIavBYWNyGhoUC3urAACIZUAVi5Xp1cFQMabFdbvwEayJMHQrGHGrTNm5877e/x8/X3+bn6MaWBo4aN1DU5f9YEMHAqAIJBYAjAAfDHgBOK4BZuAVDgALBAWpxwNOZEiLE1qNTc0jQpIJeB1kgiQLhmoRmHDB1WyTLTSM2GCzg6IXDA3QAFFHkqTFmryj+nT6FGlf9ab2o0cQNHucSFatssNE7iSVGZypQudxs7Cvp4lqMXA3oQJJP4hIHClZJaXnMHE4CQVF+ndP2rs5wiVeoA1G2nsUABjYLp2m1alXJly5cbtcTsT1NPd1kNoiJUwJeRBIeOzDVqRMDqbWwNgSkgjDGaJQoSDClihM6aIXcjBaS5d4BHv6NLf0l+mjAZM0eWL9BjpM9ZY1mcG5nt29Nm79/B69OMeXx4qOW7m3eKXn179+bZU47/Ht98cPT72ce/n3/+9vr7s0Q/AAPMrMADEfRPPQITfGTABjNhEMIJIZTwHwspBM6qDCnBkMMP6fNwn4RILNHEE1FMUcUVWVyRpRb/YYxRxhlRBNFGG0W8MccbeezRx812BDHIH4ks0sh8huQwySOZbNJJA590ZMkoqaySyCknxNLKLbmkUMsGv+xSzDHds4CC+wCgwAIrzURTTTLhjPPGDwKo4IIALqgggA+spNNOPPXkU85BCW2QAxI54PLQhBIt1NFH96OAxDO3lDQhSiHNVFPw9DSiAjE7rXPTUUm17E4jLhDzVDxLbdXVpzwIwAMyY5311VtxvaeDADogc9decw1WWEosCGDNMYs9dthlmV1khDifbVbaaamt1tprsc02OBq57dbbb8ENV9xxyS3X3HPRTVddF6sKU9t3tXVXQ3jprZcTeSezV999/1mSj99/AWYEXygCLtjggdHMx4trIFlCI0myeuIsRyY22OLvEObsCZMSasQjKRJg6hFWnKEkYicqZiTlSVa+2OVKMtbsZEY+fkIB7CBp+ZGZdZ6i50d+flloKKeSmZTpGsJFAdaeQ4Uk7ZDuwwsvvpqJKO3G2I0NBNawTeSinjvgjyzkAEmO4pbehpBTSPFFa5n2GMINQIauO2GpjE5nCAPEiOWJmgVKZ52bvRAZJLmWUYwKBBIgSAp3tmFl7K20OCCBim7Jxe2NUSn7rLD4rgsdu+2OeZGsnjtjAIgYAFyroLBJiwp3OD6ibImXPsJxiQlIanLPl37lIi6GB8CX1f/RYCshomwqmXShTVckq7CoiIcewhBTzHV3EHdC8YnCcQAVnreArBBsUBEggevIIkKXsYhIoIn4wfotMMCedzl6KrJCWqElUrMA2RAmah/xmUbeRgQ8ALAxu0PZFkajwC+kbwvG6Eja0LCaALRtg95bGtzwkDvm5O9l+3OUUZxHQhXO6zyZSoAsVhhDgrVLhjUclQltmENC4VCHPSQTD30YxC0BUYhFfBIRjZhEIyGxPzNzEM6UGEQeau1yOUPgwyzhREZoMTPFyVgUqzVFp73QivfgovQMJyUvgtGHYjReAUxhmjHAEXwzQcBn4jaRPD4BNaro2m4SMAbXeE0KSGv/wEj6MgQsNA2RfinEHAiBPzYWbIrcqcsYELAFOlLkLJ+BoEJAp4xgqEUopLhkX8pHCs3NrAEPa6Qi14iLYyiSHIPpxiQt5kbGUc45GzmaQjopil8aIHXne8JSHHe7MgzvfyKDnSxj4hKPvFIrvsPlwfzlszHGBRCtfIcCF9I4kPQPlPZTRF0M4LdTevMWAtAFKx/mFrhIUy3yzI1WBnPNi7lxInAEpCBNo5BkNOQzw/RfRUbJG1kW4p9kwKAD9WgEctzmnlgQoO4oCstgNE2flMxmR0GapY+GlKQHYmJJUbqgkaaUpe45aUthapmXxpSmeFtpTXF606d8Mac9nWkn/87YJNd5jKf/COqEjnqge1bFKAhl4U4VIQfTQDE4UExq0bDDMEsMVRFcXQRtQHTVS/BFEkFzxFWPClZIeMSrkbBcJtoqhY+1jIcPMOYdgZrGy2gVrvOJ6xTUyiGxYuKv+kCrXmeHRaLiowCjq0RhDWg8yeTLplNoAAyD8dBTmOE0DNgDOa7RgDXEMTVckIP9vAAGZTT0C3YIRRHSaQQCLOCVXOuJNVSbNaxJIRdM0w42ZOsMAM4WcFpjwCYV4hbfINcAU2Pobp9QwNdOdpB/AChQoOsEjummMcpJx2gfV4ClnWYmp3GuVAMIwFZEULTK8axEHyeKPTqhj9k5X1Z2g/8ECW6waxvLXWsU4ptMhkRsazhN04Ah3e6epr7RJeXc8pDHSEqBo+09jTvfogqOAiBk6YlKQIYSGFWapQC9UIX6dMILgiDOAaCt5d+ukY1TDriDpyDCbG68AAEKgJoMs0YWZKyMFkvBb6NEGWl2fAodh6xm3/NlHdXK3MIlRsgvFhyV24FjsYxYCfAwZwEwuzFBDOPEJYaokoHClD88YMoUdsD16Iky5oQMxYnFxiedCufINWEULG6Ak51Y5LVoZMBocTCbrQCM7N2MzGlJ4UahgI5QJsMccrWC+pzRYQckoMM1w+tT11M9czIzIwQ2gGjX5xK/EKR2qOCrAUvitDL/aMVzhP6NABDQ46zGsiQJcVowWGecWwth2DW7XUiGGeVkW6HVFP7KUFJG6qYqZAG2TdrG9gDM2qyafEKJCwAL4ZFqcweZfLF2Q079BfwVtI5SWIrvRtHqY0OUDMGOwlkKzREGgFt2H4EdtGtzB/jN+sg/KWbtqHuMhPymAOL0dBrr2sG+uLMsuwj4kV2CZjh2L3CWjsk6q0E2Ch5Zx3C0pyK/Ye64iHIR1lOLxgUA8yZrNRvgFIY4aw5bj3BcCtnDwsraqYuNOEaWmf5yH+xaarTAPL4TUcUuFxBuZqtlqYkJsBedgenZ/Xqcw6QCOiHTZ5YDOsxPcDn9buzQA0Bd/+rOUPQ6fn5xqzv1D48+jDkhA+Osj9AJDiAAHeHcYVBfSBHulC3awpC82mgNDRZVLR0T+GphSzCQtB65UIILXNwMwbZjm3wCYYG1i44v88MdhDSMuzAwNDcKA+1Na1kvMe5Edw/VUaxDE6/dayBtDo/TjrYJfFEF0FH28F2NGfrN+9cnzfG6a+9z7cA7xxVvYUmLIH65Y1yTAIaBrWv9B4n5hV8sDfmjT3DtQYKW6ptzI6+IzkEjyMcBPp95C6hLbHQXdafOsGg9jYpZteWtKoOudMr/9AEAtaXqpKKpxKEADfABkcQBIXAC70UCKfACYcYCMXADN6T/OPADBUQDQf9wBCnrw6JisCqBZ3rCDBDrgSLBYfADsgSEqkjQQXQKvRKABp+IyFrw6/aA+LaoIAYg6rLA7yILxtLvq6KAZPoBBadBIADn1QyorSJGCmuQaCpLCuzqKz4tEwaLb27NytAoMsCiB10QaG4PH5yw44zsESCrCnXwCqnCA3suzAbpxjjL/j5LK56PtPTrkeynzhyhD12imM4gCgwJrCYMxqyGd2DLwpyhvZogv8agtQqBYwCjvE4vt6zN81rrD4EsuBAMEfdQ9w5xD9AAaXRjFAoh+8RLOQpN0GiKh0Jsy5RmF0qMGAQx48xM7MZgyMbBZ9iv8HpRCD0iKxQtnu6tfCr/DQlT5hRAYc5izsyo7BdByxTGB7HWbGq+yce8aAwQ4+eQjMkSLQq8iX9qocZQYdKgkbfGDMngCCkmaxZvinosQjKADy3SLdWwgNt4zNfwSWK4bhH8Mc4cBxieiTasyciekdAWbtUW6rdCg972rWsmzxs9wsb6sdjK0dDQMXDK5uCsI9uUruZGwQGGEaYirhbuKOgsjsAEkhdLTgB47tX4ppYEgByAMMfSzCCR0RyVESTyjiEVq5P4TsWqkTDKRhb7onGirt8cKeViqaKybCbpIRmlRxYm0h7TD8y4Afj4JoPEay7okYZmJ3cIAPFeY/H6q/mGj7SYjwZXxzRIYSeF/4+O+OInI2ocFHHDiPKAzK6/1Gu/NKpstu9vyE/qoqnzrME0KiLGgsv8SBG+xKwVRW4v8zG/gGkNXiwB0lAlRVAOU+Z4/O+nrjBlNs0ATVMON3A1WfMCXfM1JzA2ZfMBabM2S1M+1mU3ebM3ffM3gTM4hXM4gRM3zdI4kTPUknM5+aGomBMEnfM5OTA6pRMDqbM6KfA6sRMCtXM7VdM7wbNfwjNbiLM8zfM8f3M8Q3A5u3M2mbM9ufM91TMD2XM+O0Q+7RMv8DM/GaFNOONNWNM/rQBA+VMK/ORO8mRPXvNAAUVBC3QKFmUNGuU1I9QIJvRBn8BS1gBTWFNDjYBDMf/UCULlU3BzREOUClYlVXAzRU+UCmolOV+0RafgV5KTRmVUCpIlOXP0RqUgWpLTR3k0SIV0SOUEPY30SJG0W8QhSZm0SY9UOXEzL2rwS+BTihqQBKkUOaUUS6G0Nrd0BLPUOL8UOruUSSIAAs50AsLoSqskAzAAAiQAAl4lTG1kAiAAAjBAEUggBEQAACBATfkhAiSgS8aUP850UDPgTyFBUBXBBCIAAOz0HxT1R+i0TuVUESTgUf0UUPeBUbmkUPcjAt40AxKVUy3hBAY1UvthUn2kUkFEVSMABO5UAxL1TjfgT2sVAkBABOz0TUPgBO7UBABAAt5UV2UVAkgAADT/4E4hYANu1VYnIAQgIAQ2AAAEVVQxYFBFIASSVUfYtD8iQAMiIAJK1VrvNAJ4VVentQSsdVDVtVmftVnlNF41YFiLFQSONVlF9Vx9NQMAoFgxoASW9U4zIE51lV2bFQPSFFIhoE8DxFU/BFYf1U4LVlNZNVFJwE7VVGEB4FbtlVThVFk11Qk0AATa1QlCYFA3gE9j1V83IE9ftkdAFT/C1U7jdAKIVQREAAQkQGOttV4ZNWSJ9WRV1QluVQSIFWQHVVyt9VFvdWMH9QkwQFgVtQQggF2ZFgJOgGTrVQPqtUAglkNgFVEhoGKd4E9L4Eyh9VIZNVIz9WzV9G0lQFrx//RkE9Vf/TQDPHVbJwAEqpVHZpY+whUAgPVPvdYJJEADVPVwg1ZNY7Zt5/VYy/ZtN3VYHxVynUBQRWBgIaBeFTVmITVPJzVa79akyjRi2ZZszXZTSxYARKBZx5ZhLRduLRdjAcAE8jQChBUAUnZYWTZqhxUEQqBVv9VQ67VWcRYDdDZbFxdo3dVxczdV5XRqAYAEJtdi4/ZypTdzJeBoAQAEPDdZrZZdT+BRWTVWt9Z0Ce9G7LRuGfVuKfdPoxVPYTd1ZTd+s9dc8RRmoVVaqfVkneB1gddbPSxUv3ZZ1VRt0bV5T/Zzo/d+73RU8Xd2MbddM+BYMaBrCdZgQQBhOf/Vek21P8JWW6LVYQG3ePeFctVXQewFBHZXZlHYXjKAWxNkhK8wcGHzdFkTh7NThzft0cBjqBBQYSSErDphiF9QCPWzgJ1OkrwDNOIwSnYDSE6Xb/aPEhbg+cqurwrvM58hihmhtwIgIqIQjKdBBucmJwAzH6B4iZ8KAbb4BTtocvIqIJ8BvKgAspBYZTjziiuBCAELYSAWjjOB09xOnO5BiL34KrA4HLK432AmlkbmKBKjitZYDZU4OFC47jDh7xSCjjmhjTNjFUjJ46ZCfMYgncz4EeoCY063sSwij/xHB+vi0ZqmEp/DthontVIjFt9sMvngxsZLOgwsEpmgEyn/0bR6TwqiTmR4WRlCC7ySGSa2axFYAYqq+TOew5MpmbVQ0b4ICQs0UWBQWAAlSL+05jOzgQB6BzLH+PQKZ368RxCsLZyHMAHEMA7cB/PeuWk0EQFqKRYK6u/yzRAG0zAcixiH+buUY7p8Y7pGYrO8ixCn+ZshjJzXtwoQatIaQJyskOAUwSs7CAFKzBPBsQHkMfYWrSp78h4fACm1ws+4IJ+1C4Acghtr7uco2ReXwSB1D4jlLAxExhhekp1lKQs2DhBoDBttic8yGXwSmv9KkAh+w89EJwmnIBsKRxyXDMA4iAEOIielYJdA4wEEb0m/ABTGEcCmYBsFCvgIoIoK/xrOxMGPt24mtY7OcCwj9/recvHEdpomq6wU0i4cpOR0JePgYMcK0YmZrU2jzoIvbOwkhwAhn40oNELG+A0iaQ0grZCZX+giB8Afm42aSdIRkuEBLGc4hMmA4k3WXE3k4E0IKzL6YjggcM0UteN2dKbm2mu0OfIJQmZ9ALosfgs0cGOUUzuRUKY3vIffCAIlu44kAg6ZDMOJ7ewdzu2ONCIju3sZCYy0PfsycQKo72ZEqACW9abn4C4LzlG4qwh5qA6yNYIv7qkMlOHtrG4xmpjtmMepwqEm3RuLBiAijIcco4mr00zAERLp7AJ+cM0Z2MErk47djpEmuynkKCfshP/Qv9Ph9kBVADkO5PabyPbGCFja5DbBnbRBDNYsDbLRtDwTLBTrfFiBAWROLTw8F25mutPOKAADnZwMxnciLRFJ+sJS687Qu/9y6eBRsOdiIm0GDeDnvMVjcWThoI7rCK6hxwtJvRxA+bQisr3IMZ1gxj9CujgT95APuMKgLzyDO7ocitLN+GbJJS7qCOASloTh9wwgGVJoLlnjnOGaFC6c8irxMq/PGBOTymkQVDmZMOH8CLYgZWoOzkPxnT9GccSHnxsIigXoNLxcn28stt7Z/Bo9JK5od8JPftJCoVbmsQ3gyFFmzRmaob57ycEbLfIc8uRc5KID0Jm4PqjAihv/AZ0eYJEfSxpIsyqSvROAArsdwQHMEDyenYlbgpAbISxyEDOu3Ty6vRL2GIufSRKoPYaJnQp+OI/xWB8AJzVrWLaqZGbDUnrMnFnGfVvGOAIz2kvRPYf7XTZ52D0DHkhWORPy3SnWkGIIHMVhkGZaggE7cKr/ZeFL6TibExJqJyU/Gy8OHhP2uOM3PoueegqyeA3iWPqyosOYUAqNuOkmXqqn3TfMWzcp0zvGTaK8D2JKvmGqnd9ZuBHmjZEj5OMvIeEXYehT0AwNud4YXiwGwhG4Sv9i3sqtmZI9y64r43y8gCwtI64r4tSkPQgvweIBQoepYN6emQGQebcA8Q41/+GbJ8yTx9gMulmOlDmTQgGOFoyYTcOYBz2a35xzgAYP7lCUp6CWC1/eR+HcDtG9EQEmVFG4f37gn+CaHUETe+y0Joy5xBixbJw0Wg4Rppnzw+bJKOLzz2kePyKbWbHOO0ici3n0A/+0mOvWBaDBxDPow3jhcFqjZDoY20dzTl8dm/rOjtqXZqwaArqKGu3QMMxxxNGPR/7rtCpz3qnnIQ219aK1u18gYBomJo0kKv/fZ0e1zHDNeqyW9gz1/yflwYEzvb7UPcgaZ7owuoG5mHIKEAkICIHAYRAAIAGHwEJQGACcBgBBAAhAkYbAI+mVUq2BBrJg3RoEimnVuPDC4//wo7xut9PvyoLXiEQgXEEtDQXwYQGgIQVMeSEeFGwVMlYB+IVBIg0cZlVGEZQdMAgNHQAiVWKdxmXetSYyLhqkZsExxLryfYYJ7gquLg74FUwe/FnpXcnlJScxKHTFjRYeLP0FIkoWGpjBGgwkBBAw1BEhNSTIARMOccJOcp8xgouTS+MCFBQdHYQPpYECsIrWtFLqAvFClE+egYFWHARQgKxZEmYULypL9soSnVNcADyzFwyJxCgK3jgaxEeBsSSVLlW5Ra4BKIWeBATUhyDdAiJOFizohgUMnI0LvdyqVVLNAloAaMJJkGAKOIEBkch8CsopzmBEBflpgNBLgon/dywuoigAwZtnA7bUEsiTiBEDBhJgy8LSC4FAAvCJ1TqnJdRuSYiGTEmyJSq/gANBJZvAHsthDgA8YNQ1SgGgQgfsBNDTWGQkP4OK6eQ4TWfUzjSfpIgWY7LZrCYhuHQKwb+/Q/JqUhCRcUWVlogZ4gXTiu/JvXj50jdAOLEDC/x9pjJEgRd2AQIZPlyIwfThCaEoiJuIlILLCK7+GZJga2pfiNiDPXJ3m2h8Z5dRRM8Q8sRVXnXaKYDXc5u0w1EA4czSDjnpzVGIc+Ghsl0UhQB3XINGPEiJhABQ6MUCvA3RAHlH+EYMQEhcF9FnBppTIozhKJCdgxDGaIgAIH73/5RZethGGx5GIpmkkkvCqA+TSD4A35NTHiblkXEUSaWWUWo5JZddJvMlk0ERJ1pssoE5R5prsrnMEFa2GaeW0zVSG4By4pmnnnkWAidtWT4J6J6DElqooWpieaiiizKapqBLPtqopJNS+l+ilWKaaaWRJsmppp+CqudsnoYqqjCkJsNNNKVWFCeqrMIaa6d3ykqlQn+eegeIfJDy4BTIjdHIdCjB+upFxtaarLKXIrqsoVhcYgdMgSxQkpOzdIZEAmWGimwzk4Abrrjjkluuueeim66667Lbrrvvuksrq+XtxWAAAuwXrIULMOAPGfe9uYAROJKDXAHkQHtEN9Wuyv9RY4koUDBj0CDhABmxeuusphlrbKusJR1wUknnWLnFAwKkU9xpZRkBRV9eFHBZwnvQ3AcdvW6bD2OeHODnxh0D7UjQi3KspyJXHK2zM70eYEADDxqjCkJr6cYWikHOXC04ZU5rGhNOkhRNz7IWPTSjZZttJNp4LiXyRKWFNtphnJxmRtVLvKHgzFEkwB0cXZtE5nq6AGAx2Wl3vDbiaMZKrzHl3ZtvAzQe4Js5AIsjcEcI5FtAXpf0NOSu2rVjDLANEJszxos7qzjrRL6+57BTzr567LW6fru8urOZwGVPqoo776FaQEFaAFBgwfCOLt88obk7z+QHAVRwQQAXVBD/wAfRe8y992xC/z2SHIDLgfhMhn9+8+mrTxEF4BrfPpLsy387/fXfkf0QFeCvdv//fwuAhbLeEC4gQNnAK4EKXCADG+jAB7LrgITyQAA8IMELMg6DGsRTBwLQgQ2CkFkhHKGWLBAA5ZEwhPdLoQBHwEIVvjCGMpwh7GhowxvGcIX9gyAPe+jDHwIxiPESX/GOlzwc1hCJOTzf9Kp3vextT4nlkOISz0e+SZiPirvTIgh1qKn3TSJ+XBTaGEfoRU3pj3plbNYaNXjGTBHwem1s1RzdKD8KWrCOGdGjBN+YqQ5+UI9+rMNmQOWJQhXyCz47XPtMiMI6Iqtf7RhSMw7p/4s4RUsTWfKEJQeVSD8kkkqgDEgouzRITLmQj8YygAKmdrEllVJSnKSknmIZSyrdEkyn5GOmjIUyOOTrMgOLCAOaoqFKWA4U9jJGFQhAuA0ZAmHIQVE6nCCcBGjuE3+xhuSSwI6e+SMQ+fJLFRixr2Ee7D2o+F1/REKikxWAGNgcpYfMkQRtYNNwh5nKOc35m64QIJyJ8Met/sRL/PlyLOcgg1taRoXcMMElAkjKLvbyAO4EtE4giVjh/mUFBEQCLnX7EYue4LDS8AUZBFAmIwLDSgY4IS4mM8JMGoCGpAGgLNwQBXekUK19VNQYF5WDyYaqzgZMZKYsIuVWWOq0lP8VFCPsEyJVq5qutPnymUqjAlAFEgiIlKQKrcCJNv7RSe+4YzNDCUhf6OkwsMFhlt4Alk8CUhC60MEJYXCAQjuKgAeYgQybkc5Sy4qPu1qHCwRwQMgYgFi3ApQhYIvqseS0y8Vd1pRJYuXFBNCAz4Jkb8C4xSwmGoCZgGIvErUFR4tjnwF0hZVA3UxY4LRYVDAkMFX6w1y6qqBNtNYZOXrKUnIy29RySy79IQ1LnsGduOGVb6ahjzdAS9H5WRaJmdUSsgSkU38Ic3NACkQlqKlMg0HnCxzqhVphWwgyuNUP3fRmKSpxU4K+yBLUwat8GjEfOZQkM1MY7HHr+UzKBS7/p4GgnB+e8Z3IeoMBxCCGeirrKu1ilXe5HFQmzVRhZ5F2VhfG4Xa7d7sNy84iDkhZx4BEywyCD8NmK/FBMTVVGQ+NxjWm1I1tgZ0XxxUZlD3UkDFyiQ6LEGjs6yShkPwkJ9dBCFZyivp6fM9WmuaVd2Byo4p8EShvUWNLrk+h3GoHLifhyJG6KLFS+pxvfVjJ2f0Ci10SsGFG7JsJI9hR7vsbE7EHLhzpyTTlw5FwpHMbzZHmbwyNz6C0Q77+YqOc40TlJi+VSWpWi58uLT4rm6avKyOpy8gr5FOVus8tFWdw3ZCE3WDjoyFNWE17kRV13ksgs66FUjUpmDC37klP/4uIoDNRhasVm1c44cOwsekISOQGOcaAyBAYoE6d1YVDIRuQm0NkzzJEOkQcXeY9qbHo85COAAvQp2nSsWdiQlMccBh2rongOcep+hshOpgxI8KROEt1znODwyqotjnoiBY8ki2GF8BqBTrFAhHtvYReH6GLTbA3IFh4LB2Gkdw9Bi1jREk2ukmeUb7lzSxjWAxmuPORPxjXrbeNQyqYc+CO3ycQFvXbdENLDnXSYtRGBQVS81PqW3QhkWpggxguBrKTdAMNNH3K5CKqSYBbuE0W4WyWR1o1Kvwu4Q/dkNP6aotYBPRiEtd4rhR8hS5kBSprDwZ09/GG2k5xxkwChv/J69P3+KzXtYZlzXdOFPNMWyIc4+i2cdKM82sMfretwDgtCs4WxTKWowkfK3wc0oujMSLq88grHxyu2RH3wR9lSXc2vaqEUogdRBDKFz7Gi4TMZGHu+emvQHojH4RBYeL7tQ6iJZ0iSieOSV8xhzMTEg3mK7vdbXYtiZLLEr1OZ7Z1fopCnbIRV39dtXDoStypO5TWdKMBzVWA3xJe/i+gn8xta8pqLqEgrIwe6zBek44JuUhfE02GMQl+NEf0oUgayEf0nQM1KIaBVYt8LAA3PEhlHIGDvceIrJbFmUjxHZy9PNNmnJtTkIK6Jdj9iR2KFAB89IiO4JvsjV5/2Z7/Q6GPwH0KKzVMHYCZqAjgjq2JbsGB4BjZ/YAaDfUfpPAgmJDCVFSIvNFGDnIXDRLhDh6h/AxhoXhZshShkmThFD4LFJrKSOSYFLIOmEnZnnwSqVyh4xmJE2qdF/JJ7ukfI4WhnHhCGuLW/LQdlLGZJ8EHG85BHDoMitkMkbmhnCCbtz2OtIWBM10NMwnUwlDM84jhmqDZmQFZMmyaHAgimJwhrjSDH/7NIFXhGy6CzVVfy1GBEr5aOhAAQ51WJhiFDuod+viDMTSinkFBs2kOwbADTmhIErCbdGGBweCZSGhD5UhIyLTbU0Bgy3xbMGkTPljTg2QTvkEj7YEGW7FT/z1lWiMuohmU0xLwWYsUzIjIoBGi3qAohMUN3k0IR3LUoXWkh+pI4ixCCnPwnHLVIWw5G8vknHJYnRcMnZDkx9WN3W4lhsX8VPWhTMoZwZBYV3rE1PjFnx883QJE5ABEBhbclH+UhJnpoxJOpEP1RUJqWcz8W6AUomU9n3GIHy+YTOFEn4DxTT6q4ySqDRTUhRo0yD5ezXd8nSeYXhL0RJRkHvBlIjDsAlp9AmD1HocgGdgQQOVYyWa0lTk1Qui1xFROlssIAF95gSLQE0/CIzLQ1uag1YkEnonFWKEcoAZ6IHSQQjyRTq71xyWmY6VBChQ4QCR8RF+CnVc4GwCewv/M4Z9GqR9Ptd+p3N3BIWRwwUI3NKQazpsrwlZVgoJsWSQ+YqRlWhciAJc7kQhzFNZfKuBZXkNiIAHeuJ3czGBe1kon1Y4V4uSfRBrp0CUhLEEuUsPX6eZamkZsmOAAxMgTOGbPxRtCIMCZ0FtXhSV4XZJ4HJ8fWCN0SliIZMF/FYV8ZNpcnmZAfJ3lcA52BIJTqiRsykon+Y6ibCF2oQ8gKpHWNIoD4OX+MQ+J1aZUwScSrRjijGIVzSEXts9/vlB7+o+ADuhKspCBGlSybCImhc+D4kGFPWgl8p9lWVWGaugk5CeRwCGcrSHi3ZJjxUG+kKD/BUiE/l9tUOiK3uH/WXwoOiaoKnXKfoIhkoCgn/RLAsRFf8qWHTwoKOKoi8JoHFQoXtph1lUZL80GOpVjNB0ib1KjE8iTWlbbpCXB6iVBAzhAtv1TPFEjK0hFS0CCPLoTtZ0Wh1wjdPrBttnlItRiPTHTsqnXmzwlEQiaqwETQb2FQFEpNV7bbdGbGECbwVjbNmCOuhVjEi0pjcbB1IFWEqDkOvJjyvnUXkjc9lUMGbxMxEBWJCykHCzBGeCFAmjZ2+0W1W2URjJUeviBYToCPp7iUJ3cawRf56UDrMnBRmokq8EUqLJER7IG013BqU4qHI4aSZod8n0Pg7JOk5KelWINHP4kAhDY5z0N/z22XOUkwFBBlnGJqepw6TrBX+FdK1dJJVDRw+K5lpduw1npQleQJR9AnEZJaksMYzFcaxWApechgrR2iNSE2tdZyowKkhzYHwKwpt605GQip5O8nGloFfulgakGYsqcK1ZIRVygg2isZxxcX8p8JquGVtudg0IhAmC+ZCeVX0wCZipapheMrA9GRyJy1Ej1wsJiQ8NW5MExBbBxj7NiFsJaiF2Q51MKWnNeK4pYTplAhdw0mHBYK7g6g2gOVMAQ5TtikwWu6RCEF266UyGYVFwymXnhpi7gXnSChDxxJH6dq3bGSI743dG+pcvc2cEVHdAOTxFlxBG1EbTOUJIayf9m8OiTyCeeVMv00dH3NJH1YI/2zBHgypDgYoQNdkl/dpn6XFEhZNHfIqjBfg8YFYIYrZHQfm4bqk8a8Q8kjZCEClAlmm6bxJEBsS742OgdLMDH8aEeuG6LeQrs3lEFOSr/3a4dNAWGIBKRHhDwtg8gDa/GpkjIvMEvGUKjPcihQem7Ym31foehSdLK2UIDGAY0Lio5koVZcOk4XW2QdAUkfBhAIYczEdsVFNr1WoPrBdSfde3KjaDmEIOpei1nXJPmGAEyPgijde/1tuk7WoEuMiO35Z36ONLzSte9Kk2ugZRd0JqqSlxrrB4G79ov3cEWEF2rotpDmWTDcarOMYD/S0WMC8PUVKqikTbV60GBUMiaBg/A/RamU2VkaSQrIqTg63GGZ5CUFdxaTeQwXLwqO01mWYAB87ZPKh1sWGarMeCEeere3lQcFFhexgWD00CNNIgvMqTr3UzCM10Utw4VXUGCvgrHDSoSQN7hFu/wwdmXVqJCmb7a1EDUHcrcH9cMxtkxdSreoXKI50Xw6Q6PbehVtWhpIdMBwxaxa9jxwBGlM6GvZVaNaoLsGqgBGdAszaLMbpKEWUDYcoBxfhitqVWXZ16F193Mw2WaZtLB+0myzFrrYFayZJ7J4jIy71hE01bMmUgy7x1g/67yUDAgUXIL+foscAqG3NCe0Soa/ygsAU+1WSrP8jLbbYK4sp8FwGV0U/+qMii9l8N4zQF786uOSHPGbfpR0httaD03kO4IioUCoPPQ57L0rpYkbpLxSRfhsx5khuI+auy2zz8raFvakf0Ec7PS5gYp9IFGdPTQM0FDNKVI4ETos6ZV9IsOrvLK4k1SdEE3Slc4gJR8NIxCGUiiqNpaVly0tCaS9EDXo5YwNG3UNFs+a6Xk7WqBNA5yyk6nSU+P303jSUZH2SRgXY7iSUvLlYjFznbhBDvUSf4GCTR+b9UhGvAZzKONUllVg5pySFfgm1b3lb38iHDsxZ9u7aQhwqBC08E4YxEoYjLZ2ETLwcs0A1TTYf99ppeMvo5VUxdf+LAJizBH1NrelNsDmJnDvl4TMNVoKsFJrBRHaNTIWLb0Xiq3pkQUTxRHWcxDstxFUZRRO/SeFIlfw4JxNBNuwPUb6OJd39MjWgHDeGMVkNwtUgMy/d4VxOki/3RKH/ZqoUG6ivG2UBwnXALH+cJOvEE/XPN0gV5peUO5NcJ1E9hyRw1oIIRYpfElGBbn7XVO01yfmJxIkhKwcqtDvunJQsyvcoYXhAZva+AqyqVp/ZwS1zdxD61xDzZMtlTMSmzC5scb1B09XVs+XIaAiXBXzF8eb/ZEzF/GdvFIeXK0iN/73W/mondcjcXf+QKBVWtUFoPW5Mz/vIYBybH4LE2eO8QiMBc3o0CYm4nzZTQtkCghFhQngy0VkNxLizCCBaK1W89pdqcZA+MbgRGzj+OIZEJlHsSl2X742fA1zaEsM50mxhqXZCMZzeraSbhs9EFfmQdmGOBy4+ltyCGOkJ4uU/e1QhUgdBg5uDYnklUzLKhUO0RfnXvn6xEBcLNzfre5Xg4NnH+unGNQSAfcRWN0ll+QoysppDeypPcRSlv68jD6pGv6pgszptuZUhf2p4P6Rpu0Gu5hmij6miCZk1G6fZ56jbN2TLP6FsI6PtvzrvN6r/v6uUi6uzKGm66FNhrB/w6bjhfAAIc1m1YvAI/zZUMwKggU/7k1kz4wOT8wMHqR0azjtLcTN0wbprA61BBbgywv1KqWOzYfAay6hCs+g1BhlBIaZhNTJrOC+33me5LB9LqSA78uWDcH8iWcscAfgb+72RV4ByUgg78bcj3k+r6j575bBExv6YItOzmccy1TIG1zssHrspsJ2MpCpCCfrJ52u8RfqMqnfCCyNAZq58bHGxkUJzQDcrtjYIZwG9n2eTS5czQVJ76z/HkOPcjRxuHegWrrAVJTddE/odMjC+byLqlTBNO7p9MzCd/Sgd9KfKynOtYrSeM+EeSqvNfXOtgzyeYOQed2vUajvZKI7hCQLsW7/dsnieoW/a/rPbDbvZLMbv/fA74U4VHgEz4OOW/hI74MTXDiMz4LUXHjQ37kS/7kU37ln8XeY37ma/7eW/7Td36wfT7Rhz4Wjv5rlr7wnH7Tpz6rmL2Atn7lv/4Upo/VL0lHH0vxworS62eS+EYyJFLsHyEzvPGDFG9B0f5IFw5LbdmppQ1g3/ofgqgg9IRXJj18AD8P5kFmtIS1PsnxJ0lQL/+NBo3zLzUgFtQtcFrLr34GjetzBvBs95vLSWmuma+9jUVXC7dBkBtbXzUQBISHAMCQEDYAS+IwgAwcjFAEQEAQRIWBqqCgeC4QhCXBsVxmnwwAgTpNAhrCxALdfje5hi3CWwhrEyKwmxMSsBL/KmB7GrobKDraGpCjW4BEUmBA2OIbAOTCSgxYHA0gQyu6W2VtdX2FjZWdpa21vcXN1Y1VbZO6a1BiUBjwMlhQOIC0WwooLjBoExhmc1AKULoTSLgLQBRQAEgGeAhXQEwjE4WUQ10VBfC2KpCrMtD0okQjWvBaWCgggI+BgWgYBGAzpg0ZSAYauNtmJwG6MsIQ7gvQD5UxZAf8LZgILhoWagCsxftGDw27h82K1QEwERIlAlWcuWQnraS1g5SudNsVVOhQokWNHtXVq0GVOwV+EfCIyqnJAOfiDUDAFIseUldXOXwi5WbDLUIKppMGgN1UVvBuHqAHashPAAegBDBA/7emNAdMmaj8lHYgWwCc+txxe8BuJ7p0nWZNk1WrAK703qpcsvaXM8NCEOSEfPNqzq1lnaqk2wzpatatXb822uuBvMICggHo6fgXbrzOPgYsmUofKy9eHdAbh8Yq2nVFWrY94xVuPW1Sz8zOS+aelE+a7hxk01LUwOdWYLZFhL3Adbzb0AJw+luA/OAu62JW69ziS2b5l4R+ACdVSPJuCfDaAQo2BRdksMHVerECjFMGkCSAM3SDxLOrQKoqIFNsGi6NLcRShJJPFFFLwvnUQYSdCrNhwglKpquwvY0UaW8LGBNwBw01EmBjPLxerMQRNAjY4hscDRiGC90EOeUfKP88VIML6fBjhwFAkKDEkChAq8IwT0hTUkPDeEzQQTXXZLPNNN10RTQ4Y0ltCWRCRAoeowDabU5bIPQzUEEHpQXQQeUktLpVHODGNT2H2qLHRGExdFJLL3WzUkw35bTTXDT1NFRRgwJ1VFNPvbRUVFdlVTVdtnMzQzx3QbRVxE5J1IACAqTVVl9/VRUWBKLTJSdZ6lxioloebcU3SVtp7NmkZhWqnP6skDYWY3cxdgAFrr0l2F/HxVTcVvgA95ZtYUFWHGppfZe4bEmNVxdk25Vl3Vy2TaDPcMkF2FRzWbHLTiSrUgsU7hRuSpEKq3CDHE0O+89hKC7EAq8jEWkkCjj/hCiGIVAo64MPz37ytiop3NCQAShgvKOzA741DxNS2FCjFDQqdMBkj43o44oswArD5zpAKQASQBQw5IyH59kSIBRNgvnfgK/udOBVBGBqGeWkKEccsMNZSZWljPAugQaIwZaVm24b5hk8RZGnuOecFYcijDRCy6qZFyCAofYafUW0qZyCJLwGdoIZbmLu3Shp8ySiiI8HcpoJPjKIoO4eBjhKZtsD5pVFa6xPV9N0H/1yoCqByuqtrGgyU0Uuj/mIrt2b2IKqXbpnjGuzkM+q667s0jkLLyEJmqPfOPW54gF6cvKisqaeimrrjVDpjAsGDv5SFTL9sz17+JSBcPRe/1Fnn1DVmSDcQLySW4L+RzKi7g61b3Jvlbf38x3HgCcHAJJhOfBhT14a9ROrgANwiCCe3SQVAF4hQ1k5SQAC6gOMAm5tgRs5T2G4sYDw2WF8LPFL287ntSWcJCntg2Gg3gc0Ex7mRF25IX44BA3jEUAJ4GBAk1J4E56pEDECvA9utoS3lHkjZ3gRIsrAMI7lVUkKbIuZWUxCsww9IRpVSmERkRVFd3hJGWAAxAF2eMJIGE83O0yWv/4UQzpmahfDqiNSHkC6tPgnYN5KVy1mmEdCfmoXsCqkgmbDDH3ZSle8emEiJdmaQU7Sku67ZCaJUklNdpJNnPSkJUEZSlLCZmaUpSTkKVG5ytiw0pX+e2Us7ShLV8LOlrfEZS51uUte9tKXvwRmMIU5TGIW05jDpGUylblMZjbTmc+EZjSlOU1qVtOa18RmNrW5TW5205vfBGc4xTlOcpbTnOdEZzrVuU52thOVQQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18800=[""].join("\n");
var outline_f18_23_18800=null;
var title_f18_23_18801="Finger tendons expanded view";
var content_f18_23_18801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Finger tendons: Expanded view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture reveals the complex relationships among the tendons and bones of the finger and clearly shows how the flexor digitorum profundus travels through the flexor digitorum superficialis to insert on the distal phalanx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harwood-Nuss A, MD FACEP, Wolfson AB, MD, FACEP, FACP, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18801=[""].join("\n");
var outline_f18_23_18801=null;
var title_f18_23_18802="Patient information: Follicular lymphoma (The Basics)";
var content_f18_23_18802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15857\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\">",
"         Lymphatic system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/28/40386\">",
"         Patient information: Lymphoma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/9/8339\">",
"         Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Follicular lymphoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/follicular-lymphoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6557612\">",
"      <span class=\"h1\">",
"       What is follicular lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Follicular lymphoma is one type of lymphoma. Lymphoma is a cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make and store cells that fight infection (",
"      <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"       figure 1",
"      </a>",
"      ). These infection-fighting cells are also called &ldquo;white blood cells.&rdquo;",
"     </p>",
"     <p>",
"      When people have follicular lymphoma, their white blood cells become abnormal and grow out of control. These cells can travel to different parts of the body. Often, the abnormal cells collect in bean-shaped organs called lymph nodes. This causes the lymph nodes to swell.",
"     </p>",
"     <p>",
"      Follicular lymphoma usually grows slowly, but it can change to a type of lymphoma that grows quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6557619\">",
"      <span class=\"h1\">",
"       What are the symptoms of follicular lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with follicular lymphoma first notice 1 or more swollen lymph nodes. These swollen nodes are often in the neck, groin, or belly. People can feel them under the skin, but they are usually not painful.",
"     </p>",
"     <p>",
"      Other than having swollen lymph nodes, some people do not have any other symptoms for years. But other people can have symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Night sweats that soak their clothes",
"       </li>",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Blockages in the digestive tract or urinary tract",
"       </li>",
"       <li>",
"        Feeling very tired and weak",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6557626\">",
"      <span class=\"h1\">",
"       Is there a test for follicular lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you and do an exam. He or she will also do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Lymph node biopsy &ndash; A doctor will remove one of the swollen lymph nodes. Then another doctor will look at the cells under a microscope to see if cancer cells are present.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6557633\">",
"      <span class=\"h1\">",
"       What is lymphoma staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphoma staging is a way in which doctors find out how far the lymphoma has spread in the lymphatic system or in the rest of the body.",
"     </p>",
"     <p>",
"      To find out how far your follicular lymphoma has spread, your doctor will do an exam, blood tests, and an imaging test, such as a CT or PET scan. Imaging tests create pictures of the inside of the body. &nbsp;",
"     </p>",
"     <p>",
"      Your doctor might also do a bone marrow biopsy. For this test, a doctor will take a small sample of bone marrow (the tissue in the middle of your bones). Another doctor will look at the sample under a microscope to see if it has cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6557640\">",
"      <span class=\"h1\">",
"       How is follicular lymphoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, follicular lymphoma is not treated right away. Your doctor might not treat your follicular lymphoma right away if it is not causing any symptoms. But he or she will watch your cancer closely by doing exams and blood tests until treatment is needed.",
"     </p>",
"     <p>",
"      Doctors usually treat follicular lymphoma when it causes symptoms. Treatments can help reduce symptoms, but they do not usually cure the cancer. The right treatment for you will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your symptoms",
"       </li>",
"       <li>",
"        Where the follicular lymphoma is in your body",
"       </li>",
"       <li>",
"        Your age and other medical conditions",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with follicular lymphoma can be treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        Medicines called &ldquo;immunotherapy&rdquo; &ndash; These medicines kill cancer cells by recognizing the cancer cells.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        Bone marrow transplant &ndash; This treatment replaces cells in the bone marrow that are killed by chemotherapy or radiation. Usually, only people whose follicular lymphoma comes back after treatment get a bone marrow transplant.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6557647\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for follicular lymphoma involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What will happen if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6557654\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=see_link\">",
"       Patient information: Lymphoma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=see_link\">",
"       Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/23/18802?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15857 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18802=[""].join("\n");
var outline_f18_23_18802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6557612\">",
"      What is follicular lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6557619\">",
"      What are the symptoms of follicular lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6557626\">",
"      Is there a test for follicular lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6557633\">",
"      What is lymphoma staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6557640\">",
"      How is follicular lymphoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6557647\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6557654\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15857\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\">",
"      Lymphatic system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/9/8339?source=related_link\">",
"      Patient information: Follicular lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=related_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_23_18803="LV and aortic pressures - two methods";
var content_f18_23_18803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    LV and aortic pressures - two methods",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    LV and aortic pressures.",
"    <br>",
"     (A) Two high fidelity pressure transducers on single catheter across aortic valve. Note normal LV diastolic wave form with early diastolic pressure as lowest point with slow increase in pressure across diastole \"a\" wave after atrial contraction.",
"     <br>",
"      (B) Fluid filled LV catheter and femoral sheath pressures. Note ringing artifact of fluid filled systems. Note overshoot of femoral artery pressure and delay in upstroke from central to peripheral location.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18803=[""].join("\n");
var outline_f18_23_18803=null;
var title_f18_23_18804="Metyrosine: Patient drug information";
var content_f18_23_18804=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metyrosine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/25/2452?source=see_link\">",
"     see \"Metyrosine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Demser&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pheochromocytoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metyrosine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12185 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18804=[""].join("\n");
var outline_f18_23_18804=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196116\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011108\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011107\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011112\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011113\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011115\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011110\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011111\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011116\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011117\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/25/2452?source=related_link\">",
"      Metyrosine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_23_18805="12 lead ECG WPW post ablation";
var content_f18_23_18805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm radiofrequency ablation of accessory pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG of a patient with Wolff-Parkinson-White who underwent a successful radiofrequency ablation of an accessory pathway shows a normal PR interval (*), no delta wave, and QRS complexes that are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18805=[""].join("\n");
var outline_f18_23_18805=null;
var title_f18_23_18806="Control measures to prevent surgical site infection following gastrointestinal procedures";
var content_f18_23_18806=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Control measures to prevent surgical site infection following gastrointestinal procedures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18806/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18806/contributors\">",
"     Deverick J Anderson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18806/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18806/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18806/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18806/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18806/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/23/18806/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1191970238\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical site infections (SSI) are an important cause of healthcare-associated infection. SSIs may be localized to the incision site or extend into adjacent deeper structures.",
"   </p>",
"   <p>",
"    Gastrointestinal procedures are among the highest risk procedures for SSI due to the presence of intraluminal bacteria. According to data published by the National Healthcare Safety Network (NHSN), rates of SSI following bile duct, liver, or pancreatic surgery are as high as 10 per 100 procedures. Rates of SSI following colon surgery are approximately 5 per 100 procedures, and rates of SSI following gallbladder surgery are 0.7 per 100 procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important factors in the prevention of SSIs include optimizing general health of the patient (such as diabetes, obesity and tobacco use), meticulous operative techniques, and correct administration of appropriate",
"    <strong>",
"    </strong>",
"    preoperative antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/2\">",
"     2",
"    </a>",
"    ]. Important operative techniques include antiseptic application to the skin of the patient, washing and gloving of the surgeons&rsquo; hands, use of sterile drapes, use of gowns and masks by operating room personnel. It is also important for the surgeons and operating room team to receive feedback regarding SSI rates and process compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/3\">",
"     3",
"    </a>",
"    ]. General principles of SSI prevention are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191970271\">",
"    <span class=\"h1\">",
"     ANTIMICROBIAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two key components of antimicrobial prophylaxis for prevention of SSI following gastrointestinal procedures: antibiotic selection and timing of administration (to optimize tissue concentration at the time of surgery). The choice of agents depends on the type of procedure, as discussed in the following sections. Timing of administration is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191970282\">",
"    <span class=\"h2\">",
"     Colorectal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is warranted for procedures involving the colon or rectum. The regimen should include activity against enteric gram-negative bacilli, anaerobes, and enterococci; there are several appropriate regimens (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In a systematic review evaluating 147 randomized trials comparing different antimicrobial regimens, there was no significant difference in efficacy among the regimens (although many trials were underpowered to detect a moderate difference) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/6\">",
"     6",
"    </a>",
"    ]. The overall rate of surgical wound infection with prophylaxis was 11 percent. First generation cephalosporins were as effective as later generation cephalosporins. A single dose given immediately before surgery was as effective as regimens that included long-term postoperative therapy.",
"   </p>",
"   <p>",
"    There are two major guidelines that issue recommendations regarding preoperative antibiotics: the Medical Letter and the Surgical Care Improvement Project. The Medical Letter guidelines are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ); the same agents are recommended by Surgical Care Improvement Project [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We are in agreement with the Medical Letter which recommends repeat dosing only for procedures lasting more than four hours and associated with major blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, the Surgical Care Improvement Project recommends routine redosing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Repeat dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    is emerging among gram-negative bacilli in the human bowel flora. In a study of 450 patients treated with cefotetan, SSI was observed in 26 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/7\">",
"     7",
"    </a>",
"    ]. Of the bacterial isolates from infected patients treated with cefotetan, 67 percent were cefotetan-resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carbapenems should not be used for surgical prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/4\">",
"     4",
"    </a>",
"    ]. While there is evidence that the rate of surgical site infection may be lower with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    than with cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/7\">",
"     7",
"    </a>",
"    ], widespread use of carbapenems may result in increased rates of resistance. This is especially important because carbapenems are the best available drugs for the treatment of serious infections caused by aerobic gram-negative organisms that are resistant to other widely-used antimicrobial drugs.",
"   </p>",
"   <p>",
"    For patients allergic to penicillins or cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 to 900 mg IV) may be used together with one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (400 mg IV),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (750 mg IV),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    (1 to 2 g IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191970325\">",
"    <span class=\"h2\">",
"     Other gastrointestinal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are in agreement with the Medical Letter guidelines which recommends antimicrobial prophylaxis for patients undergoing gastrointestinal surgery at sites other than the colon or rectum as described in the following sections (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235476\">",
"    <span class=\"h3\">",
"     Esophageal and duodenal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is warranted in patients at increased risk for SSI; risk factors include esophageal obstruction, morbid obesity, and diminished gastric acidity or gastrointestinal motility (due to obstruction, hemorrhage, gastric ulcer, malignancy, or proton pump inhibitor therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Appropriate antibiotics are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235486\">",
"    <span class=\"h3\">",
"     Biliary tract surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is warranted in patients at increased risk for SSI; risk factors include age &gt; 70 years, acute cholecystitis, a nonfunctioning gallbladder, obstructive jaundice, and common bile duct stones [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. For patients undergoing elective laparoscopic cholecystectomy in the absence of risk factors, randomized trials have shown that the risk of infection is low and that prophylaxis is not beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Among patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), routine antibiotic prophylaxis does not reduce",
"    <span class=\"nowrap\">",
"     sepsis/cholangitis",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/13\">",
"     13",
"    </a>",
"    ], even in patients thought to have biliary tract stones or distal bile duct stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/14\">",
"     14",
"    </a>",
"    ]. However, prophylaxis is warranted in patients with cholangitis, biliary obstruction, and incomplete drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/15\">",
"     15",
"    </a>",
"    ]. Appropriate antibiotics are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2240388\">",
"    <span class=\"h3\">",
"     Pancreatic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antimicrobial prophylaxis in the setting of pancreatic surgery is uncertain. In general, guidelines for biliary tract surgery may be applied as described in the preceding section. The risk of SSI is increased in the setting of endoscopic or percutaneous biliary or pancreatic drainage procedures done prior to pancreatic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/16\">",
"     16",
"    </a>",
"    ]. Therefore, antimicrobial prophylaxis prior to the pancreatic procedure should be expanded to cover microorganisms recovered from biliary drains.",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235520\">",
"    <span class=\"h3\">",
"     Appendectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is warranted in patients with nonperforated acute appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with perforated appendicitis should receive preoperative antibiotics and continue therapy for at least five days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/4\">",
"     4",
"    </a>",
"    ]. Appropriate antibiotics are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235527\">",
"    <span class=\"h3\">",
"     Mesh inguinal hernioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antimicrobial prophylaxis prior to mesh hernioplasty is uncertain, although there is a growing body of evidence to support this practice. A meta-analysis including six randomized trials in which prosthetic material was used for hernia repair demonstrated that the rate of SSI was decreased when antimicrobial prophylaxis was used compared to placebo (OR 0.48, 95% CI 0.27-0.85) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/18\">",
"     18",
"    </a>",
"    ]. Based on this evidence, we favor antimicrobial prophylaxis for mesh hernioplasty using the same regimens advocated for colorectal surgical procedures (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20280558\">",
"    <span class=\"h1\">",
"     BOWEL PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bowel preparation consists of two components: mechanical bowel preparation and administration of antibiotics. Mechanical bowel preparation consists of administering colonic cleansing agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    and enema, laxatives,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , polyethylene glycol, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    ) to decrease bacterial burden in the colon. The utility and safety of mechanical bowel preparation prior to colorectal procedures are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/19\">",
"     19",
"    </a>",
"    ]. This is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125365066#H125365066\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Bowel preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal use of antibiotics in the prevention of SSI is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In general, standard of care consists of mechanical bowel preparation together with oral and parenteral antibiotic prophylaxis, although there is evidence both for and against use of oral antibiotics. Two early randomized studies suggested that combined oral and intravenous antibiotics significantly reduced the risk of postoperative SSI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, in a subsequent randomized trial of 300 elective colorectal resections, use of oral antibiotics (in addition to mechanical cleansing and intravenous antibiotics) conferred no advantage in the prevention of SSI over mechanical preparation and intravenous antibiotics alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/25\">",
"     25",
"    </a>",
"    ]. Thereafter, a Cochrane Database Systematic Review of 182 randomized controlled trials comparing prophylactic regimens for colorectal surgery noted that combined oral and intravenous antibiotic prophylaxis was associated with lower rates of SSI than intravenous antibiotic prophylaxis alone (RR 0.55, 95% CI 0.41-0.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the available evidence, in general we favor use of both oral and intravenous antibiotics to decrease the risk of SSI following colorectal surgical procedures (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ). Among 471 surgeons surveyed in one study, 78 percent favored use of combination oral and intravenous antibiotics even though the evidence that both are needed is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/27\">",
"     27",
"    </a>",
"    ]. It is also well within the standard of care to forgo oral antibiotics and rely exclusively on preoperative intravenous antibiotics for prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are conflicting regarding whether oral antibiotic therapy in the context of mechanical bowel preparation increases risk for C. difficile infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18806/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2238036\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical site infections (SSI) are an important cause of healthcare-associated infection. They may be localized to the incision site or extend into adjacent deeper structures. Gastrointestinal procedures are among the highest risk procedures for SSI due to the presence of intraluminal bacteria. (See",
"      <a class=\"local\" href=\"#H1191970238\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimicrobial prophylaxis is warranted for patients undergoing gastrointestinal surgery involving the colon or rectum. The regimen should include activity against enteric gram-negative bacilli, anaerobes, and enterococci; there are several appropriate regimens (",
"      <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1191970282\">",
"       'Colorectal surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carbapenems should not be used for surgical prophylaxis. Widespread use of carbapenems may result in increased rates of resistance; this is especially important because carbapenems are the best available drugs for the treatment of serious infections caused by aerobic gram-negative organisms that are resistant to other widely-used antimicrobial drugs. (See",
"      <a class=\"local\" href=\"#H1191970282\">",
"       'Colorectal surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some circumstances antimicrobial prophylaxis is warranted for patients undergoing gastrointestinal surgery at sites other than the colon or rectum, including esophageal or duodenal surgery, biliary tract surgery, pancreatic surgery, appendectomy, and mesh inguinal hernioplasty. (See",
"      <a class=\"local\" href=\"#H1191970325\">",
"       'Other gastrointestinal surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bowel preparation consists of two components: mechanical bowel preparation and administration of antibiotics. We suggest administration of both oral and intravenous antibiotics to decrease the risk of SSI following colorectal surgical procedures (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Regimens are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"       table 1",
"      </a>",
"      ). Issues related to mechanical bowel preparation are discussed separately. (See",
"      <a class=\"local\" href=\"#H20280558\">",
"       'Bowel preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125365066#H125365066\">",
"       \"Surgical oncologic principles for the resection of colon cancer\", section on 'Bowel preparation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/1\">",
"      Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control 2009; 37:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/2\">",
"      Mangram AJ, Horan TC, Pearson ML, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1999; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/3\">",
"      Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/4\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2009; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/5\">",
"      Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006; 43:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/6\">",
"      Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials. Br J Surg 1998; 85:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/7\">",
"      Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 2006; 355:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/8\">",
"      Lewis RT, Goodall RG, Marien B, et al. Efficacy and distribution of single-dose preoperative antibiotic prophylaxis in high-risk gastroduodenal surgery. Can J Surg 1991; 34:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/9\">",
"      Kaufman Z, Engelberg M, Eliashiv A, Reiss R. Systemic prophylactic antibiotics in elective biliary surgery. Arch Surg 1984; 119:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/10\">",
"      Meijer WS, Schmitz PI, Jeekel J. Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg 1990; 77:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/11\">",
"      Chang WT, Lee KT, Chuang SC, et al. The impact of prophylactic antibiotics on postoperative infection complication in elective laparoscopic cholecystectomy: a prospective randomized study. Am J Surg 2006; 191:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/12\">",
"      Koc M, Zulfikaroglu B, Kece C, Ozalp N. A prospective randomized study of prophylactic antibiotics in elective laparoscopic cholecystectomy. Surg Endosc 2003; 17:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/13\">",
"      Harris A, Chan AC, Torres-Viera C, et al. Meta-analysis of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1999; 31:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/14\">",
"      van den Hazel SJ, Speelman P, Dankert J, et al. Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. Ann Intern Med 1996; 125:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/15\">",
"      Mallery JS, Baron TH, Dominitz JA, et al. Complications of ERCP. Gastrointest Endosc 2003; 57:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/16\">",
"      Jethwa P, Breuning E, Bhati C, et al. The microbiological impact of pre-operative biliary drainage on patients undergoing hepato-biliary-pancreatic (HPB) surgery. Aliment Pharmacol Ther 2007; 25:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/17\">",
"      Andersen BR, Kallehave FL, Andersen HK. Antibiotics versus placebo for prevention of postoperative infection after appendicectomy. Cochrane Database Syst Rev 2005; :CD001439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/18\">",
"      Sanabria A, Dom&iacute;nguez LC, Valdivieso E, G&oacute;mez G. Prophylactic antibiotics for mesh inguinal hernioplasty: a meta-analysis. Ann Surg 2007; 245:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/19\">",
"      Slim K, Vicaut E, Launay-Savary MV, et al. Updated systematic review and meta-analysis of randomized clinical trials on the role of mechanical bowel preparation before colorectal surgery. Ann Surg 2009; 249:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/20\">",
"      Lewis RT. Oral versus systemic antibiotic prophylaxis in elective colon surgery: a randomized study and meta-analysis send a message from the 1990s. Can J Surg 2002; 45:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/21\">",
"      Contant CM, Hop WC, van't Sant HP, et al. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. Lancet 2007; 370:2112.",
"     </a>",
"    </li>",
"    <li>",
"     Jung, B, Pahlman, L, Nystrom, PO, Nilsson, E. Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. Br J Surg 2007; 94:689.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/23\">",
"      Schoetz DJ Jr, Roberts PL, Murray JJ, et al. Addition of parenteral cefoxitin to regimen of oral antibiotics for elective colorectal operations. A randomized prospective study. Ann Surg 1990; 212:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/24\">",
"      Coppa GF, Eng K, Gouge TH, et al. Parenteral and oral antibiotics in elective colon and rectal surgery. A prospective, randomized trial. Am J Surg 1983; 145:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/25\">",
"      Espin-Basany E, Sanchez-Garcia JL, Lopez-Cano M, et al. Prospective, randomised study on antibiotic prophylaxis in colorectal surgery. Is it really necessary to use oral antibiotics? Int J Colorectal Dis 2005; 20:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/26\">",
"      Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev 2009; :CD001181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/27\">",
"      Nichols RL, Smith JW, Garcia RY, et al. Current practices of preoperative bowel preparation among North American colorectal surgeons. Clin Infect Dis 1997; 24:609.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dhqp/pdf/guidelines/SSI.pdf (Accessed on August 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/29\">",
"      Wren SM, Ahmed N, Jamal A, Safadi BY. Preoperative oral antibiotics in colorectal surgery increase the rate of Clostridium difficile colitis. Arch Surg 2005; 140:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18806/abstract/30\">",
"      Krapohl GL, Phillips LR, Campbell DA Jr, et al. Bowel preparation for colectomy and risk of Clostridium difficile infection. Dis Colon Rectum 2011; 54:810.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13984 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-3C221AEBB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18806=[""].join("\n");
var outline_f18_23_18806=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2238036\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191970238\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191970271\">",
"      ANTIMICROBIAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191970282\">",
"      Colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191970325\">",
"      Other gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2235476\">",
"      - Esophageal and duodenal surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2235486\">",
"      - Biliary tract surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2240388\">",
"      - Pancreatic surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2235520\">",
"      - Appendectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2235527\">",
"      - Mesh inguinal hernioplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20280558\">",
"      BOWEL PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2238036\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_23_18807="Abdominal aortic aneurysm long and short axis";
var content_f18_23_18807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67861%7ECARD%2F81130%7ECARD%2F60665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67861%7ECARD%2F81130%7ECARD%2F60665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm long and short axis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The long axis view shows an aneurysm of the abdominal aorta (A Ao An) as the aorta crosses the diaphragm. Prominent plaques just beyond the aneurysm can be appreciated.",
"    <br>",
"     (B) The short axis through the aneurysm (An) also shows the inferior vena cava (IVC).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the abdominal aorta on longitudinal ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis view shows a dissection of the abdominal aorta (AAo) and the presence of a spiral flap (f).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the abdominal aorta on transverse ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view shows a dissection (Dis) of the abdominal aorta (AoAb) and a spiral flap (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18807=[""].join("\n");
var outline_f18_23_18807=null;
var title_f18_23_18808="Indications for red blood cell transfusion in infants and children";
var content_f18_23_18808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for red blood cell transfusion in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18808/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18808/contributors\">",
"     Jun Teruya, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18808/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18808/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18808/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/23/18808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of red blood cells (RBCs) can be life-saving in patients with severe blood loss or patients with severe chronic anemia. On the other hand, RBC transfusion has significant risks, including volume overload, transmission of infectious agents, transfusion reactions, and various immunologic consequences including graft-versus-host disease.",
"   </p>",
"   <p>",
"    The indications for RBC transfusion in infants and children will be reviewed. The selection of the proper blood components, methods of administration, the complications of RBC transfusion and issues concerning blood donation and laboratory testing of donated blood are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link\">",
"     \"Administration and complications of red cell transfusion in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=see_link\">",
"     \"Blood donor medical history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link\">",
"     \"Compatibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF PEDIATRIC RED CELL TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transfusion rate for any blood component in hospitalized children remains uncertain. In children hospitalized at academic children's hospitals, the rate of transfusion of either RBCs or platelets is approximately 5 percent.",
"   </p>",
"   <p>",
"    This was best illustrated at a multicenter study from the Pediatric Health Information System of hospitalized patients who were 18 years or younger between 2001 and 2003 cared for at 35 academic children's hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the approximately one million hospitalized children in this database, RBC transfusions were performed in 4 percent and platelet transfusions in 1 percent of the patients. The distribution of transfusion based upon age was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neonates (patients less than 30 days of age) - 17.5 percent",
"     </li>",
"     <li>",
"      30 days to 2 years of age - 22.6 percent",
"     </li>",
"     <li>",
"      Greater than 2 years of age - 58.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased severity of illness was associated with a higher rate of transfusion. The most common diagnoses of patients who received transfusions were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Agranulocytosis",
"     </li>",
"     <li>",
"      Sickle cell crisis",
"     </li>",
"     <li>",
"      Malignancy including leukemia",
"     </li>",
"     <li>",
"      Respiratory distress syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies of RBC transfusion requirements in children except in patients with sickle cell disease and neonates. As a result, guidelines for RBC transfusion in infants and children generally have been established by taking standards from adult patients and modifying them according to clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In both children and adults, clinicians have sought a \"transfusion trigger,\" an absolute hemoglobin (Hgb) or hematocrit (Hct) value below which the patient needs RBC transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/4\">",
"     4",
"    </a>",
"    ]. However, assigning an absolute level is difficult since the hemoglobin level at which transfusion is required varies with the clinical setting (eg, acute or chronic) and physiologic status of the patient. In addition, the physiologic response to anemia in children is different from adults. In children, dyspnea, impaired consciousness, and other symptoms of hemodynamic compromise may not appear until the Hgb is &lt;6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    if the anemia has developed slowly.",
"   </p>",
"   <p>",
"    In stable, critically ill children, a Hgb threshold of 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    has been used to decrease transfusion requirements without increasing adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/5\">",
"     5",
"    </a>",
"    ]. In one trial of children cared for in the pediatric intensive care unit that randomly selected patients to a restrictive transfusion (Hgb &le; 7",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    or liberal transfusion threshold (Hgb &le;9.5",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    there were no differences in mortality, the incidence of new or progressive multiple-organ dysfunction, or adverse events between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/6\">",
"     6",
"    </a>",
"    ]. The frequency of transfusion and cumulative volume of transfused blood were lower in the restrictive transfusion group. An analysis of the subgroup of patients who had undergone surgical procedures reached similar conclusions, finding that a restrictive transfusion protocol did not increase the rate of progressive multiple organ dysfunction syndrome or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principal indication for RBC transfusion is to provide sufficient cells to prevent or reverse tissue hypoxia due to limited oxygen delivery. Although there are limited data on the Hgb level required for sufficient tissue oxygenation in normal children, data from animals and clinical observations of children with sickle cell disease suggest that an Hct of 20 percent can be tolerated in otherwise healthy children without adverse consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General RBC transfusion guidelines based principally upon patient's clinical status have been developed by pediatric transfusion medicine specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/2\">",
"     2",
"    </a>",
"    ]. In some circumstances, additional guidance is provided by the patient's Hgb or Hct level [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/2\">",
"     2",
"    </a>",
"    ]. These guidelines separate recommendations for patients &lt;4 months of age and those &gt;4 months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Less than 4 months of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children &lt;4 months of age are considered separately, because of their small blood volume and decreased production of erythropoietin, resulting in the physiologic anemia of infancy. Infants &lt;4 months of age should be transfused in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hct &lt;20 percent with symptoms of anemia and low reticulocyte count",
"     </li>",
"     <li>",
"      Hct &lt;30 percent in an infant with the following: requirement for supplemental oxygen administered by hood with oxygen concentration of &lt;35 percent or nasal cannulae, need for continuous positive airway pressure or intermittent mandatory ventilation with a mean airway pressure of &lt;6 cm H2O, clinical signs of significant apnea, bradycardia, tachycardia or tachypnea, and low weight gain (&le;10",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      over four days while receiving &ge;100",
"      <span class=\"nowrap\">",
"       kcal/kg",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      Hct &lt;35 percent in an infant with the following: requirement for supplemental oxygen administered by hood with oxygen concentration &gt;35 percent, need for continuous positive pressure or intermittent mandatory ventilation with a mean airway pressure of &gt;6 cm H2O.",
"     </li>",
"     <li>",
"      Hct &gt;45 percent in an infant on extracorporeal membrane oxygenation or with congenital cyanotic heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of the anemia of prematurity is discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Newborns'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link\">",
"     \"Anemia of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     More than 4 months of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guidelines for children &gt;4 months of age are similar to those used in adults. In general, RBC transfusion is recommended for Hgb levels &lt;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    since most such children become symptomatic with malaise, irritability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lassitude [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No transfusion is required for Hgb concentrations &gt;10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    For Hgb levels between 7 and 10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    the decision to transfuse is dependent upon the clinical situation.",
"   </p>",
"   <p>",
"    The minimum Hgb concentration in children that can be tolerated without mortality or morbidity is not necessarily the optimum Hgb concentration to support growth and normal activities. Whatever the optimum value, actual RBC transfusion practice should be a balance between that value and the perceived risks of transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link\">",
"     \"Administration and complications of red cell transfusion in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When deciding on whether to transfuse, the following factors should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acuity of anemia and intravascular volume &mdash; Chronically anemic children often tolerate Hgb concentrations as low as 6 to 7",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or an Hct of 20 percent, because they are able to maintain adequate intravascular volume and tissue oxygenation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/8\">",
"       8",
"      </a>",
"      ]. On the other hand, patients with an acute loss of blood and hypovolemia often require transfusion regardless of their level of Hgb or Hct.",
"     </li>",
"     <li>",
"      Surgery &mdash; A preoperative Hgb level of &ge;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      is recommended for patients who will receive general anesthesia, because lower values are associated with an increase in perioperative complications [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/2,11,12\">",
"       2,11,12",
"      </a>",
"      ]. This is especially important in children with sickle cell disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. RBC transfusion is recommended if other corrective therapy is not available or did not raise the Hgb concentration to 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      RBC transfusion during surgery is also needed if intraoperative blood loss is &ge;15 percent of blood volume, regardless of the Hgb or Hct level. Estimated circulating blood volume ranges from 84",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in infants 1 to 6 months, to 71",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired pulmonary and cardiac function &mdash; Patients with severe pulmonary disease, cyanotic heart disease, or on extracorporeal membrane oxygenation (ECMO) with decreased arterial oxygen saturation should be transfused when the Hct falls &lt;40 percent (corresponding to a Hgb of 13",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic anemia &mdash; Patients with chronic illnesses such as hemolysis (eg, sickle cell disease or thalassemia) or hypoproliferative anemias (eg, iron deficiency, chronic kidney disease, or chemotherapy) have specific criteria for RBC transfusion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chronic anemia'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H11\">",
"       'Oncology patients'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL SETTINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Chronic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief review of the major chronic anemias in childhood that require RBC transfusions, each of which is discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with sickle cell disease commonly are transfused for the following indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute chest syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aplastic crisis and splenic sequestration crisis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Septicemia",
"     </li>",
"     <li>",
"      Prevention of recurrent cerebral thrombosis and priapism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=see_link\">",
"       \"Cerebrovascular complications of sickle cell disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reduction of perioperative complications after surgical procedure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H24#H24\">",
"       \"Overview of the management of sickle cell disease\", section on 'Prophylactic preoperative transfusion'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thalassemia refers to a spectrum of diseases characterized by the absence or reduction of one or more globin chains in the hemoglobin molecule. RBC transfusion requirements vary among the different types of thalassemia as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta thalassemia major &mdash; In beta thalassemia major, patients are transfused to maintain a Hgb of &ge;10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      They also require iron chelation therapy to reduce complications of iron overload. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of beta thalassemia\", section on 'Chronic hypertransfusion therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H16#H16\">",
"       \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Chelation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta thalassemia intermedia &mdash; Children and adolescents with thalassemia intermedia usually do not require RBC transfusion. The need for transfusion typically begins in the mid-teen years and increases thereafter into adulthood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alpha-thalassemia &mdash; Survival of infants with severe degrees of alpha-thalassemia (eg, Hemoglobin Barts) has improved following the introduction of intrauterine or early postnatal transfusion but continued chronic transfusion is required [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/16\">",
"       16",
"      </a>",
"      ]. Patients with Hemoglobin H disease typically do not need transfusion in the first decade of life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H37#H37\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Hydrops fetalis and hemoglobin Barts'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H33#H33\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Hemoglobin H disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypoproliferative anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other chronic anemic states that require RBC transfusion in children and infants include hypoproliferative anemias, such as Diamond-Blackfan anemia, aplastic anemia, and autoimmune hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link\">",
"     \"Anemia in children due to decreased red blood cell production\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link&amp;anchor=H18#H18\">",
"     \"Acquired aplastic anemia in children and young adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=see_link\">",
"     \"Autoimmune hemolytic anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Oncology patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the largest groups of children requiring frequent RBC transfusion are oncology patients undergoing either cytotoxic chemotherapy or hematopoietic stem cell transplantation.",
"   </p>",
"   <p>",
"    One approach for RBC transfusion in children with cancer is to transfuse at a Hgb level of 6 to 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (which corresponds to Hct of 18 to 21 percent) which, as noted above, is the level at which most children become symptomatic with malaise, irritability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lassitude [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/10\">",
"     10",
"    </a>",
"    ]. For patients with a Hgb level between 7 to 10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    RBC transfusion is indicated if they develop symptoms.",
"   </p>",
"   <p>",
"    Others recommend that RBC transfusion be performed at a higher level when the Hgb level is &lt;8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (Hct &lt;24 percent) to avoid the development of symptoms, particularly if further marrow suppression is likely with subsequent chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/2\">",
"     2",
"    </a>",
"    ]. Somewhat higher thresholds for transfusion are used in some centers after hematopoietic cell transplantation and for children receiving radiation therapy should be transfused more aggressively, in order to maximize the effect of radiation by improving oxygenation of the tumor bed, although the latter indication is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link&amp;anchor=H876301#H876301\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\", section on 'Blood product support'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several surgical procedures or settings that are associated with significant blood loss. Before reviewing these procedures, it is useful to mention methods to reduce surgical blood use that are largely independent of the procedure performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reducing surgical blood use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, a variety of interventions have been undertaken to reduce surgical blood use. Many of these techniques can be used in older children without significant alteration of the adult protocols. Large-scale trials of these modalities in children have not been performed, although some reviews of experience are available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These interventions include reducing blood loss during surgery and preoperative management to enhance Hgb levels.",
"   </p>",
"   <p>",
"    Improved surgical techniques, such as red cell salvage, intraoperative platelet sequestration, and intraoperative isovolemic hemodilution, have reduced surgical blood loss. In addition, hemostatic agents (such as epsilon-aminocaproic acid) reduce blood loss in adults. Although these agents have been useful in scoliosis repair [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], it remains unclear whether these agents are in general effective in reducing surgical blood loss in children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     Desmopressin",
"    </a>",
"    (DDAVP) does not appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=see_link\">",
"     \"Intraoperative and postoperative blood salvage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37684?source=see_link\">",
"     \"Acute normovolemic intraoperative hemodilution\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylactic perioperative care to enhance Hgb levels prior to surgery includes the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    and preoperative autologous blood donation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Surgical procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several surgical procedures or settings that deserve particular mention because they are associated with significant blood loss and often require RBC transfusion in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trauma &mdash; Trauma patients may require large volume RBC transfusion due to acute blood loss. Extensive transfusion may be part of a staged approach to surgical repair, which can be lifesaving [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H13#H13\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Fluid resuscitation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiovascular surgery &mdash; RBC transfusion is frequently required during cardiovascular surgery for repair of congenital heart defects. There is variability among medical centers regarding the choice of red cell product used during cardiovascular surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/17\">",
"       17",
"      </a>",
"      ], particularly the use of fresh whole blood [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/18,30\">",
"       18,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H3#H3\">",
"       \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Whole blood'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      While hemostatic agents have reduced blood loss in adult cardiac patients, these drugs have not been uniformly useful during surgery for children with congenital heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/22-28\">",
"       22-28",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"       Desmopressin",
"      </a>",
"      (DDAVP), for example, does not reduce RBC transfusion requirements in congenital heart surgeries [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/26-28\">",
"       26-28",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"       Aprotinin",
"      </a>",
"      may reduce bleeding and decrease RBC transfusion requirements when patients are placed on extracorporeal life support [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. A meta-analysis showed that aprotinin compared to no hemostatic agent reduced the proportion of children who received red blood cell or whole blood transfusion during cardiac surgery (RR 0.67, 95% CI 0.51 to 0.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/31\">",
"       31",
"      </a>",
"      ]. However, the safety of aprotinin has been called into question, and it is no longer available in the US. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H12#H12\">",
"       \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Antifibrinolytic agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Orthopedic surgery &mdash; Orthopedic surgery, especially for scoliosis, often has significant blood losses requiring replacement with RBC transfusion. Several techniques have been used to reduce the transfusion rates in children undergoing scoliosis repair. These include acute normovolemic hemodilution during surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/32\">",
"       32",
"      </a>",
"      ], preoperative management (eg, predonated autologous blood and the administration of erythropoietin) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/33,34\">",
"       33,34",
"      </a>",
"      ], and the use of hemostatic agents. Antifibrinolytic agents (eg, epsilon-aminocaproic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/19\">",
"       19",
"      </a>",
"      ] and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/49/8982?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/20\">",
"       20",
"      </a>",
"      ]) and recombinant activated factor VII [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/35\">",
"       35",
"      </a>",
"      ] reduced blood loss and volume of transfused RBCs in adolescent patients who underwent scoliosis repair.",
"     </li>",
"     <li>",
"      Craniosynostosis &mdash; Surgical correction of craniosynostosis almost always requires RBC transfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/36\">",
"       36",
"      </a>",
"      ]. Measures that have reduced RBC allogeneic transfusions include the preoperative use of erythropoietin [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/37\">",
"       37",
"      </a>",
"      ] and perioperative blood salvage [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/38\">",
"       38",
"      </a>",
"      ]. However, in one report, acute normovolemic hemodilution in surgery for the repair of craniosynostosis did not change the need for transfusion and the volume of transfused RBC [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=see_link\">",
"       \"Overview of craniosynostosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other procedures &mdash; Occasionally, plastic surgery or surgical oncology patients may require multiple units of RBCs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns have a total blood volume of approximately 80 to 100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Thus, an extremely low birth weight infant (ie, birth weight &lt;750 g) may have a total blood volume of &lt;75 mL. Anemia can result from both iatrogenic withdrawal of blood for laboratory testing and the physiologic anemia of infancy, which is accentuated in premature infants. In addition, ECMO requires extensive transfusion support similar to the amounts used in exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for RBC transfusion in premature newborns depends upon the patient's clinical status as well as laboratory values and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H2#H2\">",
"     \"Red blood cell transfusions in the newborn\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the neonate, blood for exchange or intrauterine RBC transfusion may be required in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of hemolytic disease of the newborn or for intrauterine transfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H10#H10\">",
"       \"Red blood cell transfusions in the newborn\", section on 'Hemolytic disease of the newborn'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=see_link\">",
"       \"Intrauterine fetal transfusion of red blood cells\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=see_link&amp;anchor=H9#H9\">",
"       \"Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intrauterine transfusion has been performed for congenital dyserythropoietic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18808/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    has been extensively investigated in premature infants. It reduces the number of transfusions given, but does not generally eliminate the need for transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link&amp;anchor=H14#H14\">",
"     \"Anemia of prematurity\", section on 'Erythropoietin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of red blood cells (RBCs) can be life-saving in patients with severe blood loss or patients with severe chronic anemia. However, RBC transfusions have significant risks, including volume overload, transmission of infectious agents, transfusion reactions, and various immunologic consequences including graft-versus-host disease. As a result, the benefits of transfusion must be carefully weighed against the potential adverse effects of the intervention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In both children and adults, the principal indication for RBC transfusion is to provide sufficient cells to prevent or reverse tissue hypoxia due to limited oxygen delivery.",
"     </li>",
"     <li>",
"      General RBC transfusion guidelines based principally upon patient's clinical status have been developed by pediatric transfusion medicine specialists for patients less than four months of age and those greater than four months of age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transfusion indications have been developed for specific pediatric clinical conditions. These include patients with chronic anemia due to sickle cell anemia, thalassemia, and hypoproliferative anemias, malignancies, requiring surgery, and the neonate. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Specific clinical settings'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=see_link&amp;anchor=H2#H2\">",
"       \"Red blood cell transfusions in the newborn\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/1\">",
"      Slonim AD, Joseph JG, Turenne WM, et al. Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion 2008; 48:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/2\">",
"      Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002; 42:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/3\">",
"      Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004; 124:433.",
"     </a>",
"    </li>",
"    <li>",
"     Spence RK, Swisher SN. Red cell transfusion-the transfusion trigger. In: Clinical practice of transfusion medicine, 3rd, Petz LD, Swisher SN, Kleinman S, et al (Eds), Churchill Livingstone, New York 1996. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/5\">",
"      CASE RB, BERGLUND E, SARNOFF SJ. Ventricular function. VII. Changes in coronary resistance and ventricular function resulting from acutely induced anemia and the effect thereon of coronary stenosis. Am J Med 1955; 18:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/6\">",
"      Lacroix J, H&eacute;bert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007; 356:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/7\">",
"      Rouette J, Trottier H, Ducruet T, et al. Red blood cell transfusion threshold in postsurgical pediatric intensive care patients: a randomized clinical trial. Ann Surg 2010; 251:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/8\">",
"      Homi J, Reynolds J, Skinner A, et al. General anaesthesia in sickle-cell disease. Br Med J 1979; 1:1599.",
"     </a>",
"    </li>",
"    <li>",
"     Sloan SR, Benjamin RF, Friedman DF, et al. Transfusion medicine. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Philadelphia 2003. p.1709.",
"    </li>",
"    <li>",
"     Agarwal AK, Hastings CA, and Feusner J. Hematologic supportive care for children with cancer. In: Principles and Practice of Pediatric Oncology, 6, Pizzo PA, Poplack DG (Eds), Lippincott Williams and Wilkins, Philadelphia 2011. p.1152.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/11\">",
"      Carson JL, Duff A, Berlin JA, et al. Perioperative blood transfusion and postoperative mortality. JAMA 1998; 279:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/12\">",
"      Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/13\">",
"      Haberkern CM, Neumayr LD, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood 1997; 89:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/14\">",
"      Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/15\">",
"      Riley AA, Arakawa Y, Worley S, et al. Circulating blood volumes: a review of measurement techniques and a meta-analysis in children. ASAIO J 2010; 56:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/16\">",
"      Singer ST, Styles L, Bojanowski J, et al. Changing outcome of homozygous alpha-thalassemia: cautious optimism. J Pediatr Hematol Oncol 2000; 22:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/17\">",
"      Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg 1999; 89:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/18\">",
"      Kwiatkowski JL, Manno CS. Blood transfusion support in pediatric cardiovascular surgery. Transfus Sci 1999; 21:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/19\">",
"      Florentino-Pineda I, Blakemore LC, Thompson GH, et al. The Effect of epsilon-aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. Spine (Phila Pa 1976) 2001; 26:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/20\">",
"      Neilipovitz DT, Murto K, Hall L, et al. A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesth Analg 2001; 93:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/21\">",
"      Erstad BL. Systemic hemostatic medications for reducing surgical blood loss. Ann Pharmacother 2001; 35:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/22\">",
"      Davies MJ, Allen A, Kort H, et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg 1997; 63:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/23\">",
"      Carrel TP, Schwanda M, Vogt PR, Turina MI. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998; 66:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/24\">",
"      Miller BE, Tosone SR, Tam VK, et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998; 66:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/25\">",
"      Biswas AK, Lewis L, Sommerauer JF. Aprotinin in the management of life-threatening bleeding during extracorporeal life support. Perfusion 2000; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/26\">",
"      Oliver WC Jr, Santrach PJ, Danielson GK, et al. Desmopressin does not reduce bleeding and transfusion requirements in congenital heart operations. Ann Thorac Surg 2000; 70:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/27\">",
"      Seear MD, Wadsworth LD, Rogers PC, et al. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1989; 98:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/28\">",
"      Reynolds LM, Nicolson SC, Jobes DR, et al. Desmopressin does not decrease bleeding after cardiac operation in young children. J Thorac Cardiovasc Surg 1993; 106:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/29\">",
"      Stylianos S. Liver injury and damage control. Semin Pediatr Surg 2001; 10:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/30\">",
"      Manno CS, Hedberg KW, Kim HC, et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991; 77:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/31\">",
"      Arnold DM, Fergusson DA, Chan AK, et al. Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth Analg 2006; 102:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/32\">",
"      Copley LA, Richards BS, Safavi FZ, Newton PO. Hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Spine (Phila Pa 1976) 1999; 24:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/33\">",
"      Anand N, Idio FG Jr, Remer S, Hoppenfeld S. The effects of perioperative blood salvage and autologous blood donation on transfusion requirements in scoliosis surgery. J Spinal Disord 1998; 11:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/34\">",
"      Franchini M, Gandini G, Regis D, et al. Recombinant human erythropoietin facilitates autologous blood collections in children undergoing corrective spinal surgery. Transfusion 2004; 44:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/35\">",
"      Sachs B, Delacy D, Green J, et al. Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. Spine (Phila Pa 1976) 2007; 32:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/36\">",
"      Faberowski LW, Black S, Mickle JP. Blood loss and transfusion practice in the perioperative management of craniosynostosis repair. J Neurosurg Anesthesiol 1999; 11:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/37\">",
"      Fearon JA, Weinthal J. The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children. Plast Reconstr Surg 2002; 109:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/38\">",
"      Dahmani S, Orliaguet GA, Meyer PG, et al. Perioperative blood salvage during surgical correction of craniosynostosis in infants. Br J Anaesth 2000; 85:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/39\">",
"      Hans P, Collin V, Bonhomme V, et al. Evaluation of acute normovolemic hemodilution for surgical repair of craniosynostosis. J Neurosurg Anesthesiol 2000; 12:33.",
"     </a>",
"    </li>",
"    <li>",
"     Lindemann R, Haines AL. Evaluation and treatment of polycythemia in the neonate. In: Hematologic problems of the neonate, Christensen RD (Ed), WB Saunders, Philadelphia 2000. p.171.",
"    </li>",
"    <li>",
"     Ohls RK. Evaluation and treatment of anemia in the neonate. In: Hematologic problems of the neonate, Christensen RD (Ed), WB Saunders, Philadelphia 2000. p.137.",
"    </li>",
"    <li>",
"     Meliones JN, Hansell DR. Extracorporeal membrane oxygenation: the role of blood components. In: Supporting the pediatric transfusion recipient, Chambers LA, Issitt LA (Eds), American Association of Blood Banks, Bethesda 1994. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18808/abstract/43\">",
"      Remacha AF, Badell I, Pujol-Moix N, et al. Hydrops fetalis-associated congenital dyserythropoietic anemia treated with intrauterine transfusions and bone marrow transplantation. Blood 2002; 100:356.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5910 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18808=[""].join("\n");
var outline_f18_23_18808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF PEDIATRIC RED CELL TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Less than 4 months of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      More than 4 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SPECIFIC CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Chronic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypoproliferative anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Oncology patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reducing surgical blood use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37684?source=related_link\">",
"      Acute normovolemic intraoperative hemodilution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=related_link\">",
"      Administration and complications of red cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/59/18362?source=related_link\">",
"      Autoimmune hemolytic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=related_link\">",
"      Compatibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10582?source=related_link\">",
"      Intraoperative and postoperative blood salvage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10841?source=related_link\">",
"      Overview of craniosynostosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10665?source=related_link\">",
"      Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_23_18809="Possibly effective emerging therapies for heart failure";
var content_f18_23_18809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Possibly effective emerging therapies for heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18809/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18809/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18809/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18809/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18809/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/23/18809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic heart failure (HF), generally defined as NYHA class II to IV, is associated with increased mortality that is due primarily to progression of the myocardial dysfunction (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of HF is aimed at three goals: improvement in symptoms, slowing of disease progression, and prolongation of survival (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in symptoms can be achieved in appropriately selected patients with systolic heart failure by a variety of drugs, including digitalis, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, and aldosterone antagonists, as well as by cardiac resynchronization therapy.",
"     </li>",
"     <li>",
"      Prolongation of patient survival in appropriately selected patients with systolic heart failure has been documented with ACE inhibitors, beta blockers, aldosterone antagonists, cardiac resynchronization, and implantable cardioverter-defibrillator therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to medical therapy, consideration should be given to possible reversible causes of myocardial dysfunction (eg, coronary revascularization and cessation of alcohol intake).",
"   </p>",
"   <p>",
"    Possibly effective emerging therapies for heart failure due to systolic dysfunction will be reviewed here. These interventions have been shown to have promise in small studies, as described below, but the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio and true efficacy remain to be proven. Standard therapy for systolic HF, the management of diastolic HF, and unproven therapies for HF are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=see_link\">",
"     \"Unproven therapies for chronic systolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33208803\">",
"    <span class=\"h1\">",
"     SINUS NODE INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HF, an elevated heart rate is associated with worse cardiovascular outcomes. An elevated heart rate likely reflects activation of the sympathetic nervous system, a component of the neurohumoral response to HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H15#H15\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Neurohumoral activation and heart rate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The SHIFT trial investigated the effect of heart rate reduction using the selective sinus node inhibitor ivabradine on outcomes in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/2\">",
"     2",
"    </a>",
"    ]. 6558 patients with HF, a left ventricular ejection fraction &le;35 percent, and a sinus heart rate of &ge;70 beats per minute were randomly assigned to ivabradine or placebo and followed for a median of 23 months. The primary endpoint was a composite of cardiovascular death or hospital admission for worsening HF. Patients in the ivabradine group experienced the primary endpoint less frequently than those in the placebo group (24 versus 29 percent) largely due to reduced hospitalizations for HF (HR 0.74, 95% CI 0.66-0.83) and reduced deaths due to HF (HR 0.74, 95% CI, 0.58-0.94). Patients in the ivabradine group with an achieved heart rate less than 60 bpm at 28 days had fewer primary endpoint events than those with higher heart rates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic bradycardia and visual side-effects (phosphenes) were more common in the ivabradine group than in the placebo group (5 versus 1 percent and 3 versus 1 percent, respectively). Fewer serious adverse side events occurred with ivabradine compared to placebo (3388 versus 3847).",
"   </p>",
"   <p>",
"    SHIFT demonstrates that controlling heart rate is important in patients with heart failure. However, a limitation of the SHIFT trial is that only 23 percent of patients were receiving target doses of beta blockers. Although both beta blockers and ivabradine reduce heart rate, the evidence for beta blockade is much stronger, and the available evidence does",
"    <strong>",
"     not",
"    </strong>",
"    support use of ivabradine as a full or partial substitute for beta blocker therapy for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/4\">",
"     4",
"    </a>",
"    ]. While beta blockers have proven efficacy in reducing all-cause mortality in patients with HF due to systolic dysfunction, ivabradine had no effect on all-cause mortality or cardiovascular mortality in SHIFT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .) Ivabradine might be beneficial in patients whose heart rate does not respond to full doses of beta-blockade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMMUNOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy appears to be of no benefit for an idiopathic dilated cardiomyopathy or myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, some patients with a cardiomyopathy due to chronic inflammation, which develops as a progression of an acute myocarditis, may respond. This was illustrated in a trial of 84 patients with a dilated cardiomyopathy who had evidence of chronic inflammation on biopsy, as evidenced by increased expression of HLA; the patients were randomly assigned to therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or placebo for 100 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/7\">",
"     7",
"    </a>",
"    ]. There was no difference in the primary end point (death, heart transplantation, or hospital readmission) at two years (23 versus 21 percent for placebo). However, immunosuppressive therapy was associated with a significant reduction in LV chamber dimensions, increase in left ventricular ejection fraction (44 versus 24 percent at baseline compared to no change with placebo), and clinical improvement (72 versus 21 percent with placebo). These clinical benefits from immunosuppressive therapy were maintained after two years of follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link&amp;anchor=H14#H14\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cytokine activation raises the possibility that the immunomodulating effects of intravenous immunoglobulin (IVIG) may be an effective therapy for HF. This hypothesis was evaluated in a report in which 40 patients with an ischemic or nonischemic cardiomyopathy were randomly assigned to IVIG or placebo for 26 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/8\">",
"     8",
"    </a>",
"    ]. IVIG, but not placebo, increased the plasma levels of antiinflammatory mediators and produced a significant elevation in left ventricular ejection fraction from 26 to 31 percent.",
"   </p>",
"   <p>",
"    In contrast, a second trial of 62 patients with recent onset of a dilated cardiomyopathy (&le;6 months), only 16 percent of whom had a \"cellular infiltrate\" on a baseline biopsy, failed to find benefit from IVIG given as 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    on two consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/9\">",
"     9",
"    </a>",
"    ]. At six months there was an equivalent improvement in left ventricular ejection fraction of about 15 points in both groups (25 to 42 percent at 12 months). The negative results may be, in part, due to the unexpectedly large improvement in ejection fraction in the control arm, which may be related to the use of beta blockers in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunoadsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against cardiac cell proteins, including mitochondrial proteins, contractile proteins, and beta-receptors, have been identified in dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If cardiac autoantibodies contribute to myocardial dysfunction, their removal with immunoadsorption might improve left ventricular hemodynamics. Several studies have demonstrated the potential benefit of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report randomly assigned 18 patients to three sequential days of immunoadsorption with subsequent immunoglobulin IgG substitution or to control, who received no immunoadsorption [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/10\">",
"       10",
"      </a>",
"      ]. After the first treatment, there was a significant decrease in systemic vascular resistance and an increase in stroke volume index and cardiac index from 2.1 to 2.8",
"      <span class=\"nowrap\">",
"       L/min/m2;",
"      </span>",
"      this improvement in hemodynamics persisted for three months. In contrast, there were no changes in the control group.",
"     </li>",
"     <li>",
"      In a second report, immunoadsorption completely eliminated the anti-beta-1 adrenoceptor autoantibodies in the 17 patients undergoing this therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/11\">",
"       11",
"      </a>",
"      ]. After one year, the mean LV ejection fraction increased from 22 to 38 percent, LV end-diastolic volume decreased by 14.5 percent, and the autoantibodies did not reappear. At the same time, there were no changes in antibody levels or left ventricular function in the 16 patients undergoing only standard medical therapy.",
"     </li>",
"     <li>",
"      Another study indicated that the subclass of immunoglobulin may be important in antibody-mediated DCM. Column immunoadsorption was performed with either protein A columns (which bind to and remove most IgG, but have a low affinity for IgG3) or anti-IgG columns (which have specificity for all IgG subclasses). Only the anti-IgG column was associated with significant improvement in cardiac index with the first treatment and at three months [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/12\">",
"       12",
"      </a>",
"      ]. This result is consistent with data suggesting that elevated IgG3 levels correlate with clinical disease in DCM [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"       \"Etiology and pathogenesis of myocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The improvement in LV function with immunoadsorption has been associated with reduced myocardial inflammation and reduced oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one study, purification of the eluent collected from the immunoadsorption column found that the cardiodepressant substances are antibodies capable of binding to various myocardial proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has been studied for its immunomodulatory effects in diseases such as erythema nodosum and cancer. The possible efficacy of thalidomide in HF was evaluated in a single center trial of 56 patients with NYHA class II or III HF and LVEF &lt;40 percent (mean 25 percent), who were randomly assigned to thalidomide (target dose 200 mg daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients were on standard therapy for heart failure including ACE inhibitors or ARBs (98 percent) and beta-blockers (91 percent).",
"   </p>",
"   <p>",
"    After 12 weeks, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    had a significant improvement in LVEF (24 to 32 percent), compared to no change in patients treated with placebo. Patients treated with thalidomide also had a significant reduction in matrix metalloproteinase-2, suggesting a matrix stabilizing effect. Adverse effects were more common with thalidomide, including vertigo, constipation, and bradycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    was evaluated in 39 patients with an idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/19\">",
"     19",
"    </a>",
"    ] and in 38 patients with an ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/20\">",
"     20",
"    </a>",
"    ] who had class II or III heart failure and were receiving an ACE inhibitor and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    . Compared to placebo, six months of pentoxifylline therapy (400 mg TID) significantly improved functional class and left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    inhibits the production of tumor necrosis factor alpha (TNFa). However, given the lack of apparent benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a soluble tumor necrosis factor receptor fusion protein that binds to TNFa and functionally inactivates it, a possible improvement with pentoxifylline may be mediated by other mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=see_link&amp;anchor=H10#H10\">",
"     \"Unproven therapies for chronic systolic heart failure\", section on 'Anti-TNF alpha therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunomodulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulation therapy (IMT) is a type of immunotherapy that involves removal of a patient's blood, which is then treated and readministered to the patient via intramuscular injection. The treatment is thought to activate immune cells and to increase the elaboration of immune modulators. In an initial double-blind trial, seventy-five patients with NYHA functional chronic class III to IV HF were randomized to receive either IMT or placebo for six months with continuation of standard HF therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/21\">",
"     21",
"    </a>",
"    ]. Immunomodulation produced significant reductions in the risk of death and the risk of hospitalization. There was nonsignificant improvement in NYHA functional classification and quality of life and no change in left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    In a larger double-blind, placebo-controlled study, 2426 patients with NYHA functional class II to IV HF due to left ventricular (LV) systolic dysfunction were randomized to receive IMT or placebo every 28 days with a mean follow-up of 10.2 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/22\">",
"     22",
"    </a>",
"    ]. There was no significant effect on the primary endpoint, time to death from any cause or first hospitalization for cardiovascular reasons (hazard ratio 0.92; 95% CI 0.80-1.05; p=0.22). However, in two prespecified subgroups, patients with no history of previous myocardial infarction (n=919) and patients with NYHA II HF (n=689), IMT was associated with reductions in the primary endpoint (odds ratio 0.74; 95% CI 0.57-0.95 and odd ratio 0.61; 95% CI 0.46-0.80, respectively).",
"   </p>",
"   <p>",
"    Thus, while the role of IMT remains to be established, there is evidence to suggest that some patients may benefit from such therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTIVIRAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence of viral genome in endomyocardial biopsy specimens by the polymerase chain reaction (PCR), and preliminary evidence suggests that antiviral therapy with beta interferon may be beneficial for patients with chronic dilated cardiomyopathy. In a series of 22 patients with persistent left ventricular (LV) dysfunction, symptomatic HF, and enteroviral or adenoviral nucleic acid in the myocardium by PCR, 18 x 10(6) IU per week of beta interferon was given subcutaneously for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/23\">",
"     23",
"    </a>",
"    ]. Viral genome by PCR was eradicated in all patients after antiviral therapy. Viral clearance was paralleled by a significant decrease in LV size and a significant increase in LV function.",
"   </p>",
"   <p>",
"    A randomized, placebo-controlled trial (BICC) is currently underway to confirm these findings. Alpha interferon may offer similar benefits, but this agent has not been systematically studied [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HORMONES AND ANTAGONISTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vasopressin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of vasopressin may contribute to the increase in systemic vascular resistance in HF via stimulation of the V1a receptor, which is found on vascular smooth muscle cells, and also promote renal water retention via the V2 receptor, leading to the development of hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\", section on 'Antidiuretic hormone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these observations, use of a vasopressin antagonist might be beneficial in patients with HF via the following mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With agents that block the V2 receptor, the increase in water excretion would tend to correct the hyponatremia and relieve some of the volume overload.",
"     </li>",
"     <li>",
"      With agents that block the V1a receptor, the reduction in systemic vascular resistance might improve myocardial function by reducing afterload.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two smaller randomized trials demonstrated that the V2 receptor blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    increases fluid removal and improves hyponatremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 254 outpatients, most of whom had NYHA class II or III HF (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      therapy (30 to 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      resulted in a decrease in body weight at one day and correction of hyponatremia at 25 days [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ACTIV in CHF trial included 319 hospitalized patients with an LVEF &lt;40 percent and NYHA class III or IV HF [",
"      <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       Tolvaptan",
"      </a>",
"      therapy (30 to 90",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      resulted in a mean weight loss of 1.6 kg after one day and 2.8 kg by hospital discharge; however, some weight was regained through seven weeks of outpatient treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more definitive assessment of the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    comes from the EVEREST trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These studies enrolled 4133 patients who were hospitalized for HF and had documented LV systolic dysfunction (LVEF &le;40 percent). Patients were randomly assigned to treatment with tolvaptan (30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for a minimum of 60 days.",
"   </p>",
"   <p>",
"    The EVEREST Clinical Status trials assessed the short term effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/28\">",
"     28",
"    </a>",
"    ]. The study was divided into two segments (trial A and trail B), based upon study site. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In both trials A and B,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      therapy resulted in a greater degree of weight loss at day one (1.7 to 1.8 versus 1.0 kg with placebo) and at day seven or discharge (3.3 to 3.8 versus 2.7 to 2.8 kg with placebo).",
"     </li>",
"     <li>",
"      A higher percentage of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      reported an improvement in dyspnea at day one (72 to 77 versus 65 to 71 percent with placebo).",
"     </li>",
"     <li>",
"      Global clinical status was not improved with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The EVEREST Outcome trial included all patients from both segments of the clinical status trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/29\">",
"     29",
"    </a>",
"    ]. At a median follow up of 10 months, there was no difference in all cause mortality or in a combined endpoint of cardiovascular death or HF hospitalization between patients assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    or placebo. Among patients with a baseline plasma sodium concentration below 134",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    tolvaptan produced a greater increase in plasma sodium at seven days or time of discharge if earlier (5.5 versus 1.9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with placebo). However, the difference tended to become smaller over time.",
"   </p>",
"   <p>",
"    The diuresis induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     tolvaptan",
"    </a>",
"    is a water diuresis not a salt diuresis as induced by conventional diuretics.",
"   </p>",
"   <p>",
"    Only one oral pure V1A receptor antagonist has been developed but data on clinical efficacy are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/25\">",
"     25",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/17/18711?source=see_link\">",
"     Conivaptan",
"    </a>",
"    , a combined",
"    <span class=\"nowrap\">",
"     V1A/V2",
"    </span>",
"    receptor antagonist is currently available for use, but clinical data in patients with HF are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/30\">",
"     30",
"    </a>",
"    ] and current plans are for evaluation only for short-term use in acute decompensated HF because of cytochrome P450 interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5577859\">",
"    <span class=\"h2\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data suggest that testosterone therapy may improve functional capacity in patients with heart failure but data are insufficient to determine safety and effects on clinical events. A meta-analysis of four randomized trials enrolling a total of 198 patients (84 percent male) found that testosterone therapy significantly improved exercise capacity (measured by six-minute walk test, incremental shuttle walk test, or peak VO",
"    <sub>",
"     2",
"    </sub>",
"    ) compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/31\">",
"     31",
"    </a>",
"    ]. No significant effect on cardiovascular events was found.",
"   </p>",
"   <p>",
"    As discussed separately, disorders including sudden death, hypertension, and left ventricular hypertrophy have been reported in individuals taking androgens but a causal relationship has not been established. Testosterone patch United States Food &amp; Drug Administration approved labeling includes a warning that edema, with or without heart failure, may be a complication of androgen treatment in patients with pre-existing cardiac, renal, or hepatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=see_link\">",
"     \"Use of androgens and other hormones to enhance athletic performance\"",
"    </a>",
"    .) The 2010 Endocrine Society guidelines on testosterone therapy for men with androgen deficiency recommended against testosterone therapy in patients with uncontrolled or poorly controlled HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link&amp;anchor=H18#H18\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adrenomedullin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenomedullin is a peptide that was originally isolated from human pheochromocytoma cells. It exerts vasodilatory effects on the vasculature. In addition, adrenomedullin and its binding sites have been found in the heart, and adrenomedullin enhances myocardial contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/34\">",
"     34",
"    </a>",
"    ]. Circulating levels of adrenomedullin are elevated in patients with HF and are correlated with the degree of left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/35\">",
"     35",
"    </a>",
"    ]. These observations suggest that adrenomedullin might play a role in the compensatory mechanisms in HF.",
"   </p>",
"   <p>",
"    Preliminary data suggest that the administration of adrenomedullin may be beneficial in patients with heart failure. In one study of 14 patients, an infusion of adrenomedullin increased the cardiac index and reduced pulmonary capillary wedge pressure to a greater degree in patients with HF than in normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/36\">",
"     36",
"    </a>",
"    ]. In contrast, an increase in urine volume and urinary sodium secretion was greater in normals than in those with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    , a selective inhibitor of type 5 phosphodiesterase (PDE-5), lowers pulmonary vascular resistance. Two small randomized trials of chronic sildenafil versus placebo in patients with LV systolic HF found that sildenafil improved exercise capacity at three months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] and at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/38\">",
"     38",
"    </a>",
"    ] compared to baseline. Treatment with sildenafil was associated with lowering of pulmonary artery systolic pressure in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/37\">",
"     37",
"    </a>",
"    ] and reduced pulmonary vascular resistance in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/38\">",
"     38",
"    </a>",
"    ]. In one of the studies, sildenafil treatment was associated with fewer hospitalizations for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential safety concerns relating to administration of PDE-5 inhibitors in patients with HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Relaxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxin is a naturally occurring human peptide vasodilator. The RELAX-AHF trial of serelaxin, recombinant human relaxin-2, in patients with acute heart failure found that it improved some clinical outcomes including a measure of dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/39\">",
"     39",
"    </a>",
"    ]. This international randomized controlled trial enrolled 1161 patients with acute heart failure and systolic blood pressure &gt;125 mmHg. The study was not restricted to patients with low left ventricular ejection fraction (LVEF) and 45 percent of patients had an LVEF &gt;40 percent. Serelaxin improved one measure of dyspnea (the visual analogue scale area under the curve) through day five and reduced average length of index hospital stay but did not improve the proportion of patients with moderate or marked improvement in dyspnea measured by Likert scale during the first 24 hours or readmission to the hospital within 60 days. The serelaxin group experienced a significantly lower rate of cardiovascular death (HR 0.63; 95% CI 0.41-0.96) and all-cause mortality (HR 0.83, 95% CI 0.43-0.93) to 180 days. Additional study is required to confirm the efficacy and safety of serelaxin as a treatment for acute heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia has been associated with reduced survival in patients with HF. It is not known if this is a cause-and-effect relationship between anemia and survival or if anemia is simply a reflection of more severe disease. Treating anemia may improve exercise tolerance and quality; a beneficial effect on mortality is unproven. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link\">",
"     \"Impact of anemia in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MECHANICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some experimental mechanical approaches to treating heart failure are discussed here. The role of ventricular assist devices in acute and chronic settings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Continuous aortic flow augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous aortic flow augmentation (CAFA) is a novel approach that does not increase cardiac output directly. Instead, arterial blood is drawn from a peripheral artery and recirculated through the aorta via an extracorporeal pump that then returns blood through a second arterial access site. The system provides continuous flow through the aorta that augments pulsatile cardiac output. Increased aortic flow is postulated to stimulate favorable hemodynamic changes, primarily through cardiac unloading and peripheral vasodilation.",
"   </p>",
"   <p>",
"    The safety and efficacy of this approach was evaluated in an initial series of 24 patients from the United States and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients with moderate to severe systolic dysfunction were eligible if they were hospitalized with acute decompensated HF requiring hemodynamic monitoring, intravenous diuretics, and intravenous vasodilator",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inotropic therapy. CAFA was provided via the Cancion system. One patient died during therapy. Seven others had transient or correctable adverse effects including bleeding, arterial dissection, and cannula thrombosis. Medical therapies, including diuretics, vasodilators, and inotropes were continued in all patients. CAFA at a rate of 1 to 1.6",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    was continued for an average of 77 hours.",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary capillary wedge pressure fell from a baseline of 29 mmHg to 20 mmHg",
"     </li>",
"     <li>",
"      Systemic vascular resistance fell from 1413 to 1136",
"      <span class=\"nowrap\">",
"       dynes/sec",
"      </span>",
"      per cm5",
"     </li>",
"     <li>",
"      Cardiac index increased from 2.0 to 2.3",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m2",
"     </li>",
"     <li>",
"      Improvements in all three of these parameters persisted 24 hours after discontinuation of CAFA.",
"     </li>",
"     <li>",
"      There was a transient fall in serum creatinine from 1.4 to 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (124 to 106",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      that returned to baseline three days after CAFA was discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More data are needed to determine if CAFA improves outcomes in appropriately selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Inspiratory muscle training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscle weakness and deconditioning may worsen exercise tolerance and quality of life in patients with HF. Respiratory muscle training, or inspiratory muscle training (IMT) has improved muscle strength and endurance in patients with COPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28549?source=see_link\">",
"     \"Respiratory muscle training and resting in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential value of IMT in patients with HF due to systolic dysfunction and respiratory muscle weakness was evaluated in a small controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/41\">",
"     41",
"    </a>",
"    ]. Thirty-two patients were randomly assigned to 30 minutes of daily therapy with an IMT device, set to 30 percent of maximum static inspiratory load, or to placebo treatment with the same device set to no inspiratory load. After 12 weeks of treatment, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspiratory strength improved in treated patients, but not those assigned to placebo.",
"     </li>",
"     <li>",
"      Six-minute walk test distance increased in patients treated with IMT (from 449 to 550 meters), but did not change in those assigned to placebo. Patients treated with IMT also had a significant reduction in the sensation of dyspnea during the six-minute walk test.",
"     </li>",
"     <li>",
"      Quality of life scores improved in patients treated with IMT, but not those assigned to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in this study had mild or moderate LV dysfunction and HF symptoms, and were not formally enrolled in exercise training. As a result, it is not known if similar benefits would be seen in patients with more advanced disease or in those participating in an exercise training program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Enhanced external counterpulsation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced external counterpulsation (EECP) is a technique that increases arterial blood pressure and retrograde aortic blood flow during diastole (diastolic augmentation). Cuffs are wrapped around the patients legs and, using compressed air, sequential pressure (300 mmHg) is applied (from the lower legs to lower and upper thighs) in early diastole to propel blood back to the heart. EECP has been most commonly evaluated in the treatment of refractory angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=see_link&amp;anchor=H22#H22\">",
"     \"New therapies for angina pectoris\", section on 'Enhanced external counterpulsation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trials and registries of EECP included some patients with HF, some of whom had improvements in their exercise capacity following EECP therapy. The PEECH trial directly evaluated the possible benefit of EECP in patients with mild-to-moderate HF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/42\">",
"     42",
"    </a>",
"    ]. One hundred and eighty-seven patients were randomly assigned standard medical therapy with seven to eight weeks of EECP or standard medical therapy alone. Patients assigned to EECP were slightly more likely to increase their total exercise time by more than 60 seconds (35 versus 25 percent with standard medical therapy). However, EECP did not have any effect on peak VO2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, this study did not achieve positive results for its two primary endpoints. In addition, the results of this single-blind trial are subject to placebo effect. Further research will be necessary to define the impact of EECP in the treatment of HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hawthorn extract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hawthorn extract is an herbal agent derived from species of the Hawthorn plant (Crataegus monogyna or Crataegus laevigata). It is approved for use in Germany for patients with NYHA class II HF.",
"   </p>",
"   <p>",
"    The efficacy of hawthorn extract was evaluated in a meta-analysis of ten trials enrolling 855 patients with chronic HF (NYHA class I to III) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/43\">",
"     43",
"    </a>",
"    ]. These patients did not necessarily have systolic dysfunction. Treatment with hawthorn was associated with greater exercise tolerance and maximal achieved workload as well as beneficial reductions in pressure-heart rate product and symptoms of shortness of breath and fatigue. Dosing varied widely (160 to 1800 mg) and impact on mortality was not determined. The mechanism of possible benefit and the relevance of this analysis to patients with systolic dysfunction is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Outpatient monitoring via device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of hemodynamics (eg, pulmonary artery pressures and cardiac output) may be helpful in the management of patients with HF, particularly those with refractory HF and repeated hospital admissions. The standard approach, using pulmonary artery catheterization, can be performed only in hospitalized patients. In addition, concerns have been raised regarding a possible increase in mortality in patients who undergo this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of refractory heart failure\", section on 'Hemodynamic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An implantable hemodynamic monitoring device may provide useful measurements over time in ambulatory patients. A randomized trial enrolled 390 patients with New York Heart Association class III HF who underwent implantation of a wireless pulmonary artery device [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/44\">",
"     44",
"    </a>",
"    ]. Pulmonary artery pressure measurements were transmitted to physicians from the 270 patients in the treatment group and not from the 280 patients in the control group. At six months, HF-related hospitalizations were significantly less frequent in the treatment group than in the control group (31 versus 44 percent, HR 0.70, 95% CI 0.60-0.84). There was a 1.5 percent rate of device- or system-related complications.",
"   </p>",
"   <p>",
"    Noninvasive approaches to hemodynamic monitoring have also been developed for ambulatory patients. Impedance monitoring (also known as impedance cardiography) is a technique that measures changes in electrical conduction through the body to estimate thoracic fluid content and stroke volume [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. Some systems based upon these techniques have shown good correlation with cardiac output measured via pulmonary artery catheterization. In addition, in a cohort of 212 HF patients, serial impedance cardiography measurements were predictive of HF events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a randomized trial that enrolled 335 patients with chronic systolic HF (LVEF&le;35 percent) found that monitoring intrathoracic impedance (and other parameters) with the use of an audible patient alert did not lead to reduction in the composite end point of all-cause mortality and heart failure hospitalization and instead increased HF hospitalization and outpatient visits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18809/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7672953\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possibly effective emerging therapies for heart failure (HF) include sinus node inhibition, immunotherapy, antiviral therapy, neurohormones and antagonists, hawthorn extract, and outpatient monitoring via device. These interventions have been shown to have promise in small studies, as described above, but the",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratio and true efficacy remain to be proven. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although both beta blockers and ivabradine reduce heart rate, the evidence for beta blockade is much stronger, and the available evidence does",
"      <strong>",
"       not",
"      </strong>",
"      support use of ivabradine as a full or partial substitute for beta blocker therapy for HF. (See",
"      <a class=\"local\" href=\"#H33208803\">",
"       'Sinus node inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While vasopressin antagonists have not been shown to improve outcomes in patients with HF, they may be of value in the treatment of selected patients in whom HF is complicated by hyponatremia.",
"     </li>",
"     <li>",
"      Various types of immunotherapy have been investigated in patients with HF but such therapy does not have an established clinical benefit except for specific indications in patients with myocarditis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Immunotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link&amp;anchor=H11#H11\">",
"       \"Natural history and therapy of myocarditis in adults\", section on 'Specific therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hawthorn extract may provide symptomatic benefit in patients with HF but its effect on mortality is not known. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Hawthorn extract'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The utility of an implantable hemodynamic monitoring device for ambulatory patients with HF has not been established. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Outpatient monitoring via device'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard therapy for systolic HF and the management of diastolic heart failure are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"       \"Treatment and prognosis of diastolic heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/1\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/2\">",
"      Swedberg K, Komajda M, B&ouml;hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/3\">",
"      B&ouml;hm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/4\">",
"      Teerlink JR. Ivabradine in heart failure--no paradigm SHIFT&hellip;yet. Lancet 2010; 376:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/5\">",
"      Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/6\">",
"      Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/7\">",
"      Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/8\">",
"      Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/9\">",
"      McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/10\">",
"      Felix SB, Staudt A, D&ouml;rffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000; 35:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/11\">",
"      M&uuml;ller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/12\">",
"      Staudt A, B&ouml;hm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/13\">",
"      Staudt A, Sch&auml;per F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001; 103:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/14\">",
"      Schimke I, M&uuml;ller J, Priem F, et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 2001; 38:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/15\">",
"      Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/16\">",
"      Warraich RS, Dunn MJ, Yacoub MH. Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: pro-inflammatory antibodies in DCM patients. Biochem Biophys Res Commun 1999; 259:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/17\">",
"      Warraich RS, Noutsias M, Kazak I, et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J 2002; 143:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/18\">",
"      Gullestad L, Ueland T, Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005; 112:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/19\">",
"      Skudicky D, Bergemann A, Sliwa K, et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001; 103:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/20\">",
"      Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004; 109:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/21\">",
"      Torre-Amione G, Sestier F, Radovancevic B, Young J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004; 44:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/22\">",
"      Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008; 371:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/23\">",
"      K&uuml;hl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/24\">",
"      Daliento L, Calabrese F, Tona F, et al. Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 2003; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/25\">",
"      Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/26\">",
"      Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/27\">",
"      Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/28\">",
"      Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/29\">",
"      Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/30\">",
"      Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/31\">",
"      Toma M, McAlister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012; 5:315.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4241 / (Accessed on May 7, 2009) file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4241. (Accessed on May 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/33\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/34\">",
"      Szokodi I, Kinnunen P, Tavi P, et al. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 1998; 97:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/35\">",
"      Nishikimi T, Saito Y, Kitamura K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995; 26:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/36\">",
"      Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/37\">",
"      Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/38\">",
"      Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/39\">",
"      Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/40\">",
"      Konstam MA, Czerska B, B&ouml;hm M, et al. Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failure. Circulation 2005; 112:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/41\">",
"      Dall'Ago P, Chiappa GR, Guths H, et al. Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized trial. J Am Coll Cardiol 2006; 47:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/42\">",
"      Feldman AM, Silver MA, Francis GS, et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2006; 48:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/43\">",
"      Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008; :CD005312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/44\">",
"      Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/45\">",
"      Moshkovitz Y, Kaluski E, Milo O, et al. Recent developments in cardiac output determination by bioimpedance: comparison with invasive cardiac output and potential cardiovascular applications. Curr Opin Cardiol 2004; 19:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/46\">",
"      Cotter G, Moshkovitz Y, Kaluski E, et al. Accurate, noninvasive continuous monitoring of cardiac output by whole-body electrical bioimpedance. Chest 2004; 125:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/47\">",
"      Summers RL, Shoemaker WC, Peacock WF, et al. Bench to bedside: electrophysiologic and clinical principles of noninvasive hemodynamic monitoring using impedance cardiography. Acad Emerg Med 2003; 10:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/48\">",
"      Rosenberg P, Yancy CW. Noninvasive assessment of hemodynamics: an emphasis on bioimpedance cardiography. Curr Opin Cardiol 2000; 15:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/49\">",
"      Packer M, Abraham WT, Mehra MR, et al. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. J Am Coll Cardiol 2006; 47:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18809/abstract/50\">",
"      van Veldhuisen DJ, Braunschweig F, Conraads V, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 2011; 124:1719.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3478 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18809=[""].join("\n");
var outline_f18_23_18809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7672953\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33208803\">",
"      SINUS NODE INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunoadsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunomodulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HORMONES AND ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vasopressin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5577859\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adrenomedullin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Relaxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MECHANICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Continuous aortic flow augmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Inspiratory muscle training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Enhanced external counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hawthorn extract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Outpatient monitoring via device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7672953\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3478\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3478|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 2\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=related_link\">",
"      New therapies for angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28549?source=related_link\">",
"      Respiratory muscle training and resting in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=related_link\">",
"      Unproven therapies for chronic systolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21050?source=related_link\">",
"      Use of androgens and other hormones to enhance athletic performance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_23_18810="Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment";
var content_f18_23_18810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18810/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18810/contributors\">",
"     Steven C Plaxe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18810/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18810/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/23/18810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/23/18810/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/23/18810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine cancer (",
"    <a class=\"graphic graphic_picture graphicRef73416 \" href=\"UTD.htm?10/7/10358\">",
"     picture 1",
"    </a>",
"    ) is the most common gynecologic malignancy in the United States; annually there are approximately 46,470 new cases and 8120 deaths from the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/1\">",
"     1",
"    </a>",
"    ]. Women have a 2.5 percent lifetime risk of developing endometrial carcinoma, which accounts for 6 percent of all cancers in women. Fortunately, most cases are diagnosed at an early stage when surgery alone may be adequate for cure. Five-year survival rates for localized, regional, and metastatic disease are 96, 67, and 17 percent, respectively.",
"   </p>",
"   <p>",
"    Preoperative evaluation, staging, and posttreatment surveillance for endometrial carcinoma will be reviewed here. Risk factors, clinical features, diagnosis, and histopathology, treatment with chemotherapy or radiation, and uterine sarcoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=see_link\">",
"     \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15257?source=see_link\">",
"     \"Treatment and prognosis of uterine leiomyosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to treatment, a complete pelvic and general physical examination should be performed, with particular attention to the size and mobility of the uterus and the presence of extrauterine masses or ascites; potential sites of nodal metastases should also be examined (eg, supraclavicular nodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/2\">",
"     2",
"    </a>",
"    ]. Laboratory evaluation or imaging studies should be selected as appropriate for the planned treatment (eg, major surgery, chemotherapy, radiation), patient comorbidities, and suspicion of metastases. Cervical cancer screening should be performed as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24201?source=see_link\">",
"     \"Preoperative management of patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative issues related to endometrial carcinoma staging are discussed in this section. Diagnosis of endometrial carcinoma is discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Assessment for hereditary cancer syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lynch syndrome (hereditary nonpolyposis colon cancer) is associated with a greatly increased risk of endometrial carcinoma, as well as colon and ovarian cancer and other Lynch-associated malignancies. Synchronous tumors discovered intraoperatively are common in these women. Synchronous tumors are simultaneously diagnosed primary tumors involving two different organs. These tumors do not represent a metastasis from one organ to the other. Women with endometrial carcinoma who have a family history suggestive of Lynch syndrome should be referred for genetic counseling and testing and also have testing of their tumor specimen for the mismatch repair proteins which characterize this syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Testing of tumor specimen for mismatch repair deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the serum tumor marker CA 125 is a clinically useful test for predicting extrauterine spread of endometrial carcinoma. In a retrospective study of 141 women with endometrial carcinoma, a CA 125 value of greater than 40",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    was reported to have a sensitivity of 78 percent and specificity of 81 percent for lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/3\">",
"     3",
"    </a>",
"    ]. These results have been confirmed by others, but the optimal threshold (eg, &gt;20, &gt;35, &gt;40",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    has not been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. No significant difference in CA 125 levels between pre- and postmenopausal women were found in the study cited; however, the average CA 125 value in premenopausal women is higher than it is in postmenopausal women.",
"   </p>",
"   <p>",
"    Assay of serum CA 125 may also be useful for following patients after initial treatment, if levels were initially elevated. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Posttreatment surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic or abdominal imaging to assess myometrial invasion or cervical involvement is unnecessary if surgical staging is planned. In the infrequent situation in which a patient is staged clinically, contrast-enhanced magnetic resonance imaging (MRI) appears to be the best radiographic modality for detecting myometrial invasion or cervical involvement when compared with nonenhanced MRI, ultrasound, or computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The majority of studies reported the sensitivity of enhanced MRI as approximately 80 to 90 percent (range 57 to 100 percent) for myometrial invasion; findings of sensitivity for cervical invasion were inconsistent ranging from 56 to 100 percent. Thus, a negative study does not provide assurance that complete surgical staging is not needed.",
"   </p>",
"   <p>",
"    MRI is also the best imaging modality, compared with CT or positron emission tomography (PET) with or without CT, for detecting lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. However, preoperative imaging for this purpose is not necessary. Lymph nodes should be assessed intraoperatively in all women with endometrial carcinoma. This evaluation should consist of, at a minimum, palpation of pelvic and paraaortic nodes with biopsy or removal of enlarged nodes. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Lymph node evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A chest radiograph should be performed as part of the initial assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STAGING AND PRIMARY SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinoma is surgically staged according to the joint 2010 International Federation of Gynecology and Obstetrics",
"    <span class=\"nowrap\">",
"     (FIGO)/TNM",
"    </span>",
"    classification system (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79873 \" href=\"UTD.htm?7/7/7291\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2010 classification system, the definition of stage I was changed to include only two substages: IA (tumor limited to the endometrium or invades less than one-half of the myometrium) and IB (tumor invades one-half or more of the myometrium). In the previous surgical staging system for endometrial carcinoma, stage I had three substages: IA (tumor limited to the endometrium); IB (tumor invades less than one-half of the myometrium); or IC (tumor invades one-half or more of the myometrium). It appears that the 2010 staging system is better able to predict prognosis than the prior system [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/17\">",
"     17",
"    </a>",
"    ]. Therefore, when discussing studies published prior to 2010, we will use the older surgical staging system.",
"   </p>",
"   <p>",
"    Surgery alone is usually curative for women with low risk disease (endometrioid histology, grade 1 or 2, confined to the endometrium [a subset of stage IA], no other risk factors for persistence or recurrence). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link\">",
"     \"Approach to adjuvant treatment of endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgical staging overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total extrafascial hysterectomy with bilateral salpingo-oophorectomy with pelvic and paraaortic lymph node dissection is the standard staging procedure for endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/18\">",
"     18",
"    </a>",
"    ]. Vaginal, laparoscopic or robot-assisted approaches are also possible (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Other surgical approaches'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    As with other intraabdominal gynecologic malignancies, complete staging includes biopsy of any areas where metastases are suspected; most surgeons record results of peritoneal cytology, but these are not part of FIGO staging. Cytoreduction often is performed when metastases are evident. An omentectomy is frequently done for patients with serous or clear cell histology. Pelvic and para-aortic lymph nodes sampling or removal are performed selectively. At a minimum, these nodes are palpated and enlarged or suspicious lymph nodes are removed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intraoperative gross inspection and frozen section",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterine surgical specimen should be opened in the operating room to evaluate disease extent. The extent of uterine disease provides some direction as to the extent of surgical staging that is called for (ie, whether lymph node evaluation is needed), which, in turn, may impact on recommendations for adjuvant treatment. A meta-analysis of 16 studies including 2567 women with endometrial cancer evaluated the diagnostic performance of intraoperative gross inspection to determine the depth of myometrial invasion and found a sensitivity of 75 percent and a specificity of 92 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6650537\">",
"     'Prevalence of and risk factors for nodal metastases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Frozen section of the area of deepest invasion may provide additional information, but studies comparing results of frozen section with final pathology have not reported consistently high concordance, especially in low-stage and low-grade disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. Variable concordance between specialist gynecologic pathologists and general pathologists has also been reported and is of concern [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/27\">",
"     27",
"    </a>",
"    ]. As an example, in a large study (n = 482) of women with grade 1 endometrial adenocarcinoma, the grade on final pathologic analysis was higher than that from intraoperative frozen section in 15 percent of patients, 1 percent of whom had a grade higher than 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, another study (n = 784) found that clinically significant discordance between frozen section and final pathology evaluation occurred in only 1.3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lymph node evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important prognostic factors for endometrial carcinoma is the presence of extrauterine disease, particularly pelvic and paraaortic lymph node metastases. The approach to lymph node assessment is controversial, particularly in women presumed to have early stage disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6650537\">",
"    <span class=\"h3\">",
"     Prevalence of and risk factors for nodal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of nodal spread varies with tumor stage and grade. The risk is 3 to 5 percent in patients with well-differentiated superficially invasive tumors, while it is as high as 20 percent in poorly differentiated deeply invasive disease (",
"    <a class=\"graphic graphic_table graphicRef58580 \" href=\"UTD.htm?15/26/15788\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the presence of any of the following variables indicates a high risk of nodal disease, even in apparent stage I disease; therefore, the presence of any of these features suggests a benefit for surgical resection of the lymph nodes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serous, clear cell, or high-grade histology",
"     </li>",
"     <li>",
"      Myometrial invasion greater than 50 percent",
"     </li>",
"     <li>",
"      Large tumor (&gt;2 cm in diameter or filling the endometrial cavity)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6649498\">",
"    <span class=\"h3\">",
"     Anatomy of pelvic and paraaortic nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Gynecologic Oncology Surgical Procedures Manual, pelvic node dissection includes removal of nodal tissue from the distal one-half of each common iliac artery, the anterior and medial aspect of the proximal half of the external iliac artery and vein, and the distal half of the obturator fat pad anterior to the obturator nerve (",
"    <a class=\"graphic graphic_figure graphicRef52298 \" href=\"UTD.htm?26/50/27425\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75242 \" href=\"UTD.htm?37/44/38596\">",
"     figure 2",
"    </a>",
"    ). Some data suggest that removal of the circumflex iliac nodes to the distal external iliac nodes increases the risk of lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paraaortic node dissection consists of resection of nodal tissue over the distal vena cava from the level of the inferior mesenteric artery to the mid right common iliac artery and between the aorta and the left ureter from the inferior mesenteric artery to the left mid common iliac artery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/34\">",
"     34",
"    </a>",
"    ]. Some experts extend the paraaortic lymph node dissection (LND) superiorly to the level of the renal veins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, the nodal chains that we assess when staging endometrial carcinoma include the left and right paraaortic and, in the pelvis, the left and right common, external and internal iliac and obturator chains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6650587\">",
"    <span class=\"h3\">",
"     Controversies in lymph node assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is ongoing controversy over whether pelvic and paraaortic node sampling or complete LND should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. The status of both the pelvic and paraaortic lymph nodes should be assessed intraoperatively in all patients, as advised by the FIGO surgical and pathologic staging system [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/19,40-42\">",
"     19,40-42",
"    </a>",
"    ]. However, the type and extent of LND were not specified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6650486\">",
"    <span class=\"h4\">",
"     Assessment of paraaortic nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraaortic nodes may be positive in the absence of positive pelvic nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Some data suggest that paraaortic LND is associated with a survival benefit in women with intermediate or high-risk disease. This finding was reported in a retrospective cohort study of 671 women with endometrial carcinoma of all stages who underwent either pelvic LND or combined pelvic and paraaortic LND; median follow-up for both groups was approximately 7.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/45\">",
"     45",
"    </a>",
"    ]. Eight-year disease-specific survival rates were significantly higher in the combined pelvic and paraaortic LND group compared with pelvic LND alone for women with intermediate or high-risk disease (84 versus 69 percent), but not for women with low-risk disease (94 versus 93 percent). In addition, it appears that the potential benefit associated with paraaortic LND increases with higher tumor grades. In a large series (n=1453) of women with endometrioid endometrial carcinoma, there were 10 paraaortic recurrences, distributed as follows:",
"    <span class=\"nowrap\">",
"     0/10",
"    </span>",
"    in grade 1 tumors;",
"    <span class=\"nowrap\">",
"     1/10",
"    </span>",
"    in grade 2;",
"    <span class=\"nowrap\">",
"     9/10",
"    </span>",
"    in grade 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6649037\">",
"    <span class=\"h4\">",
"     Node sampling versus resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node sampling differs from lymphadenectomy in that the goal of sampling is to obtain a representative biopsy, while the intent of lymphadenectomy is to remove all node-bearing tissue in a specific anatomic distribution. When lymph node sampling is performed, data suggest that patients who underwent multiple site sampling had better survival compared to those who had limited site sampling, or no sampling at all [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/47\">",
"     47",
"    </a>",
"    ]. Based on this report, it would be reasonable to conclude that more accurate prognostic information may be obtained when nodes are dissected from several of the node chains draining the uterus.",
"   </p>",
"   <p>",
"    Surgery limited to TAH-BSO with palpation of nodes with sampling of enlarged nodes for women with grade 1 or 2 disease that is presumed to be stage IA or B is advocated by some experts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/32,48-50\">",
"     32,48-50",
"    </a>",
"    ]. These women have a greater than 90 percent five-year survival rate following TAH-BSO alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Of note, palpation or inspection has not been found to be a sensitive method for detecting metastases. This was illustrated in a classic report, in which fewer than 10 percent of node positive patients with endometrial carcinoma had grossly involved nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This limited approach for presumed early stage disease is supported by data from two large randomized trials and a large retrospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/32,48,53\">",
"     32,48,53",
"    </a>",
"    ]. The largest of these trials (n=1408), A Study in the Treatment of Endometrial carcinoma (ASTEC) trial, found no survival benefit of staging with versus without pelvic lymphadenectomy in women thought preoperatively to have stage I disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/32\">",
"     32",
"    </a>",
"    ]. Of note, in the no lymphadenectomy group, suspicious nodes were removed.",
"   </p>",
"   <p>",
"    However, this trial does not provide information regarding the usefulness of pelvic LND for guiding treatment after surgery since patients in the second phase of the trial were treated without taking into account lymph node status. In addition, since all patients underwent paraaortic node palpation and sampling, it does not address the benefit of paraaortic LND. The radiotherapy portion of this trial is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who do not undergo at least sampling of pelvic and paraaortic lymph nodes at the time of surgery are incompletely surgically staged.",
"   </p>",
"   <p>",
"    Some experts believe that lymph node sampling should be performed in all women with endometrial carcinoma, but not complete pelvic and paraaortic LND. When this approach is used, all clinically suspicious nodes are be sampled, but in the absence of suspicious nodes, a representative (not random) sampling is performed. The benefit of this approach is that it gives information about nodal status while minimizing procedure-related morbidity. In particular, some experts believe that the morbidity associated with complete LND outweighs the benefits when the likelihood of nodal disease is very low, such as in low risk stage I disease. Lower extremity lymphedema and associated cellulitis are the primary posttreatment issues associated with pelvic and paraaortic LND. The reported risk of lymphedema varies widely (5 to 38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/33,54\">",
"     33,54",
"    </a>",
"    ]. Risk of lymphedema appears to increase with the number of nodes removed (10 or more is associated with a risk of lymphedema of 3 to 10 percent) and with adjuvant radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/33,54\">",
"     33,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of lymphedema and cellulitis following pelvic lymph node dissection is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=see_link\">",
"     \"Cellulitis following pelvic lymph node dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete resection of lymph nodes in all patients is recommended by other experts because they believe that sampling may miss positive nodes and that therefore fail to identify patients who may benefit from adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest complete pelvic LND and extended paraaortic node dissection rather than selective nodal sampling. Given the importance of lymph node involvement to staging and treatment decisions, lymph node assessment is best performed by experienced surgeons, such as gynecologic oncologists [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sentinel node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sentinel lymph node biopsy for endometrial carcinoma is still investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/60\">",
"     60",
"    </a>",
"    ]. A meta-analysis of 26 studies including 1101 sentinel node procedures found a sensitivity of 93 percent for the detection of lymph node metastases in women with endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the sentinel lymph node hypothesis, tumor cells migrate from a primary tumor and colonize one or a few lymph nodes (ie, the sentinel lymph node) before involving other lymph nodes. Peritumoral injection of a dye or tracer permits identification of a sentinel lymph node in most patients, and its status accurately predicts the status of the remaining regional nodes.",
"   </p>",
"   <p>",
"    The site of injection of the tracer for endometrial carcinoma is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/60,62\">",
"     60,62",
"    </a>",
"    ]. Studies have evaluated cervical, subserosal, and hysteroscopically-guided endometrial injection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. The meta-analysis of 26 studies described above found that pericervical injection was associated with a significantly increased rate of detecting any sentinel node and that hysteroscopic injection was associated with a significantly decreased detection rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus about the best surgical approach (open or laparoscopic) for sentinel lymph node biopsy or the utility of preoperative imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/62\">",
"     62",
"    </a>",
"    ]. Further study is required to evaluate whether sentinel lymph node biopsy is clinically useful and, if so, the optimal site for tracer injection and the accuracy of lymphatic mapping in endometrial carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16620756\">",
"    <span class=\"h2\">",
"     Management of women with cervical involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, it was thought that women with stage II endometrial carcinoma (tumor invades stromal connective tissue of the cervix but does not extend beyond uterus (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    )) had a high risk of parametrial involvement; this was based upon an assumption that endometrial carcinoma would follow a pattern of spread similar to cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/68\">",
"     68",
"    </a>",
"    ]. Thus, these patients have been treated with radical hysterectomy at some institutions. However, it appears that lymphovascular space invasion is a better predictor of parametrial extension than cervical involvement. This was illustrated in the largest study, a retrospective series of 334 women with endometrial carcinoma who underwent radical hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/69\">",
"     69",
"    </a>",
"    ]. Lymphovascular spread was present in all 28 women (8.4 percent) with parametrial spread. Most of these women (26 of 28) had lymphovascular space invasion in addition to one or more of the following findings: invasion of more than half the myometrial depth (19 women), cervical invasion (10), ovarian metastases (six), or pelvic or paraaortic lymph node metastases (19), or positive peritoneal cytology (13). Thus, for women with stage II endometrial carcinoma, we suggest performing a simple hysterectomy (extrafascial class I) (",
"    <a class=\"graphic graphic_table graphicRef57850 \" href=\"UTD.htm?13/29/13788\">",
"     table 4",
"    </a>",
"    ) with lymphadenectomy rather than radical hysterectomy. The exceptions to this are women with gross cervical involvement in whom performing a simple hysterectomy would cut through the tumor (all gross disease should be removed)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those in whom it is uncertain whether the primary is cervical or uterine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest surgical cytoreduction in women who are found to have pelvic or intra-abdominal disease at exploration. Cytoreduction appears to confer a survival advantage to women with pelvic or intra-abdominal spread of endometrial cancer, but high quality data are lacking. The best available evidence is a meta-analysis of 14 retrospective case series that included 10 studies of primary disease and four studies of recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/70\">",
"     70",
"    </a>",
"    ]. A higher proportion of women with complete cytoreduction were found to be significantly associated with longer median survival. For women with primary disease, overall survival rates were: complete cytoreduction (30 to 51 percent) and optimal cytoreduction, defined in individual studies as &le;1 or &le;2cm (15 to 51 percent).",
"   </p>",
"   <p>",
"    Secondary cytoreduction is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=see_link&amp;anchor=H5234939#H5234939\">",
"     \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\", section on 'Surgical cytoreduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional surgical approach to endometrial carcinoma staging is by laparotomy. Alternative approaches may be appropriate in low risk patients or as data emerge regarding laparoscopic staging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of laparoscopy for staging and treatment of endometrial carcinoma decreases perioperative morbidity and appears to result in comparable treatment effectiveness in when compared with laparotomy for women with early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. A meta-analysis of four randomized trials that compared women with endometrial carcinoma who underwent complete surgical staging with laparoscopically assisted vaginal or total laparoscopic hysterectomy versus laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/63,73\">",
"     63,73",
"    </a>",
"    ]. The laparoscopic procedures were significantly longer (3.3 versus 2.2 hours), but resulted in fewer perioperative complications, decreased blood loss (267 mL less), and shorter hospital stays (three versus four days) and faster return to normal activity (28 versus 48 days). The number of pelvic and paraaortic lymph nodes resected was the same with both techniques. Data regarding cancer survival are limited, however, as only two trials reported long-term follow-up; at a median of 44 and 79 months, there were no significant differences between surgical groups in overall (OR 0.8, 95% CI 0.4-1.7), disease-free (OR 0.8, 95% CI 0.3-1.7), or cancer-related survival (OR 0.9, 95% CI 0.2-4.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/63\">",
"     63",
"    </a>",
"    ]. All but one of the four trials included only women with stage I disease; therefore, it is uncertain whether a laparoscopic approach is appropriate for women with advanced disease.",
"   </p>",
"   <p>",
"    A subsequent randomized study, conducted by the Gynecologic Oncology Group, assigned more than 2600 patients with uterine malignancy to laparoscopy or laparotomy. All patients underwent hysterectomy and surgical staging including pelvic and paraaortic node dissection. The results showed that laparoscopic surgery is feasible and safe; complication rates were similar regardless of the surgical approach. Approximately a quarter of the patients randomized to laparoscopy required conversion to laparotomy. Mean duration of hospitalization and was significantly shorter, and mean operative time was significantly longer, in the laparoscopy group. Longer follow up is ongoing to determine whether there are differences in recurrence and survival between laparotomy and laparoscopy groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a case series from a single surgeon, the rate of conversion of laparoscopic endometrial carcinoma staging procedures to an open or vaginal approach in a series of 235 patients was three percent overall and seven percent in patients with a body mass index of 40 or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important potential limitation of laparoscopic endometrial carcinoma staging is the difficulty of using this technique to dissect the paraaortic nodes above the inferior mesenteric artery (IMA). A prospective series reported that 77 percent of patients with paraaortic nodal metastases have disease above the IMA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/76\">",
"     76",
"    </a>",
"    ]. As noted above, some experts extend the paraaortic LND superiorly to the level of the renal veins. To reach this level laparoscopically requires advanced skills, and possibly, special techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic staging of endometrial carcinoma should only be performed by a surgeon with experience in laparoscopic hysterectomy and lymph node sampling. To minimize potential seeding of cancer cells of the peritoneal cavity, vaginal cuff, and port site during laparoscopic staging, some surgeons perform bilateral tubal coagulation as the first surgical step and also avoid use of uterine manipulators [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Because of these concerns, uterine morcellation typically is avoided; if the uterus is too large to remove vaginally, then an abdominal hysterectomy is preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4455?source=see_link\">",
"     \"Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link\">",
"     \"Laparoscopic approach to hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Robot-assisted or single port laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Robot-assisted and single port (also referred to as laparoendoscopic single-site surgery [LESS]) are newer laparoscopic techniques that have been used for endometrial carcinoma staging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=see_link\">",
"     \"Robot-assisted laparoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=see_link\">",
"     \"Laparoendoscopic single-site (single port) surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Robot-assisted laparoscopic endometrial carcinoma staging was compared with conventional laparoscopy and laparotomy in a systematic review that included eight studies with a total of 589 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/77\">",
"     77",
"    </a>",
"    ]. The advantages of robotic procedures were mainly in comparison with laparotomy. Blood loss was significantly lower with robotic surgery than laparotomy (an average of 186 mL less) and conventional laparoscopy (an average of 86 mL less, a difference that is unlikely be clinically significant). The rate of transfusion was not significantly reduced compared with either laparotomy (OR 0.3, 95% CI 0.1-1.2) or conventional laparoscopy (OR 0.5, 95% CI 0.1&ndash;2.2), but the study was underpowered to detect significant improvements of this magnitude. The rate of wound and other complications (stroke, ileus, lymphedema, nerve palsy, acute renal failure, lymphocyst, urinary retention) were significantly reduced for robotic surgery compared with laparotomy (wound: OR 0.1, 95%CI 0.04&ndash;0.4 and other complications: OR 0.3, 95% CI 0.1&ndash;0.6), but not conventional laparoscopy. The primary disadvantage of robotic procedures was longer operative duration (an average of 89 minutes longer than laparotomy).",
"   </p>",
"   <p>",
"    Regarding LESS, use for surgical staging and lymphadenectomy for gynecologic cancers has been reported. As an example, 13 of 15 women with endometrial carcinoma and five of six women with ovarian cancer were staged with lymphadenectomy, when appropriate, using a LESS approach; the remaining procedures were converted to conventional laparoscopy or laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/78\">",
"     78",
"    </a>",
"    ]. Median operative duration was 2.2 hours.",
"   </p>",
"   <p>",
"    Another series evaluated use of LESS for staging of gynecologic malignancies with pelvic and paraaortic lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/79\">",
"     79",
"    </a>",
"    ]. Successful procedures were reported in 20 of 21 patients with a mean operative duration of 2.0 hours. Median pelvic and paraaortic node counts were 14 (range 7 to 19) and 6 (range 2 to 14), respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vaginal hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal hysterectomy is not recommended, in general, for endometrial carcinoma staging since it precludes examination of the abdomen and lymph nodes for metastases. However, this surgical approach may be appropriate for women who are poor candidates for major abdominal surgery (eg, obesity, medical comorbidities). In these populations, retrospective series have reported that vaginal hysterectomy is associated with a low rate of perioperative complications and 5 to 10 year disease-specific survival rates of 80 percent or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, since stage is uncertain in these women, it is not possible to compare these data with survival rates for other women.",
"   </p>",
"   <p>",
"    In women who undergo vaginal hysterectomy, BSO should also be performed. Women who are at intermediate (grade 3 or tumors that extend beyond one-half of the myometrium) or greater risk of disease recurrence may be advised to have adjuvant radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=see_link&amp;anchor=H1596987971#H1596987971\">",
"     \"Adjuvant treatment of intermediate-risk endometrial cancer\", section on 'Definition of intermediate-risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link&amp;anchor=H1596994160#H1596994160\">",
"     \"Approach to adjuvant treatment of endometrial cancer\", section on 'Risk stratification and overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Testing of tumor specimen for mismatch repair deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinoma is often the sentinel cancer for women with Lynch syndrome (hereditary non-polyposis colon cancer). These women are also at risk of colon cancer, ovarian cancer, and other Lynch-associated malignancies. Thus, to identify these women, some experts advocate universal testing of endometrial carcinoma specimens using immunohistochemistry for mismatch repair proteins, followed by single gene sequencing to establish a diagnosis of Lynch syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. However, whether testing should be performed for all women with endometrial carcinoma or only for those with family histories suggestive of Lynch syndrome is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of mismatch repair can also occur in sporadic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. However, sporadic tumors with defective MMR do not contain MMR gene mutations; instead, they have somatic epigenetic changes such as promoter hypermethylation that silence gene expression and result in microsatellite instability (MSI). Approximately 20 percent of endometrial carcinomas are MSI-positive; fewer than 5 percent are thought attributable to Lynch syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SPECIAL CLINICAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Synchronous ovarian and endometrial cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synchronous primary cancers of the endometrium and ovary are found in 5 percent of women with endometrial carcinoma and 10 percent of women with ovarian cancer and [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. For women with endometrial carcinoma, the risk appears to be higher in premenopausal women, in whom 5 to 29 percent have a synchronous ovarian malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histology is often the same in both the endometrium and ovary, making it unclear whether there are two separate primary tumors or a metastasis from the endometrium to the ovary, or, less frequently, from the ovary to the endometrium. Metastatic disease to the ovary, rather than a synchronous primary, should be suspected when ovarian disease is small, bilateral, or multinodular with surface implants and angiolymphatic invasion at the ovarian cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staging and surgical treatment is the same regardless of whether the patient has metastatic disease or synchronous primaries. In cases with synchronous primary tumors of both ovary and endometrium, treatment is based on the combined treatment recommendations for each cancer according to stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Inoperable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with presumed stage I disease who are unfit or unwilling to have surgery, primary radiation therapy may be acceptable. Clinical staging should be performed for these women according the FIGO system adopted in 1971 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/94\">",
"     94",
"    </a>",
"    ]. Clinical staging procedures include examination under anesthesia, sounding of the uterus, endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, and imaging studies. Adjuvant therapy for women with endometrial carcinoma who cannot tolerate surgery is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link&amp;anchor=H215732934#H215732934\">",
"     \"Approach to adjuvant treatment of endometrial cancer\", section on 'Inoperable patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fertility preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with stage I, grade 1 endometrial carcinoma who wish to preserve fertility may be candidates for treatment with progestin therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    ). A thorough evaluation prior to medical therapy (eg, dilation and curettage, imaging studies) is necessary to try to confirm that the lesion is consistent with low grade, low stage disease. However, an important consideration is that high-risk features may be found in the surgical specimen at the time of hysterectomy in women who were felt to have low-risk disease prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/95\">",
"     95",
"    </a>",
"    ]. Fertility preservation for women with endometrial carcinoma is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link&amp;anchor=H215732927#H215732927\">",
"     \"Approach to adjuvant treatment of endometrial cancer\", section on 'Fertility preservation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6520494\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of endometrial carcinoma is determined primarily by disease stage and histology (included both grade and histologic subtype). Fortunately, most women with endometrial carcinoma have a favorable prognosis, since the majority have endometrioid histology and present with early stage disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H4678240#H4678240\">",
"     \"Overview of endometrial carcinoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the rate of five-year survival for stage I disease is approximately 80 to 90 percent, for stage II is 70 to 80 percent, and for stages III and IV is 20 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/23/18810/abstract/17,96\">",
"     17,96",
"    </a>",
"    ]. Survival rates by stage are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef68004 \" href=\"UTD.htm?30/39/31356\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postreatment surveillance and other posttreatment issues, including postmenopausal hormone therapy and sexual health, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H11157097#H11157097\">",
"     \"Overview of endometrial carcinoma\", section on 'Posttreatment surveillance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H25012651#H25012651\">",
"     \"Overview of endometrial carcinoma\", section on 'Posttreatment issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23747?source=see_link\">",
"       \"Patient information: Uterine cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"       \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial carcinoma is surgically staged according to the joint International Federation of Gynecology and Obstetrics",
"    <span class=\"nowrap\">",
"     (FIGO)/American",
"    </span>",
"    Joint Committee on Cancer (AJCC) classification system (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79873 \" href=\"UTD.htm?7/7/7291\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Surgical staging overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend total extrafascial hysterectomy with bilateral salpingo-oophorectomy performed either via laparotomy or laparoscopy for staging and initial management of endometrial carcinoma (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgical staging overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Laparoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with apparent stage IA grade 1 endometrial carcinoma who wish to preserve fertility can opt to avoid TAH-BSO and undergo progestin therapy, but the optimum surveillance of these women is not known and they are at risk for recurrent and synchronous disease. Thus, we recommend that these women undergo TAH-BSO after completion of childbearing, even in cases with demonstrated tumor regression (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Fertility preservation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest surgical cytoreduction for women with pelvic or intra-abdominal disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cytoreduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The status of both the pelvic and paraaortic lymph nodes should be assessed intraoperatively in all patients. Given the importance of identification of nodal metastases to staging and treatment decisions, this assessment should be performed by experienced surgeons, such as gynecological oncologists. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lymph node evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymph node dissection provides the most comprehensive and precise evaluation of patients with apparent stage I endometrial carcinoma (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). It is reasonable not to remove lymph nodes in those who do",
"      <strong>",
"       not",
"      </strong>",
"      have individual patient or tumor characteristics (eg, serous, clear cell, or high-grade histology; myometrial invasion &gt;50 percent; or a large tumor) associated with a high risk of nodal metastases. Women with endometrial carcinoma who do not undergo at least sampling of pelvic and paraaortic lymph nodes at the time of surgery are incompletely surgically staged. (See",
"      <a class=\"local\" href=\"#H6650537\">",
"       'Prevalence of and risk factors for nodal metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with endometrial carcinoma who are undergoing lymph node evaluation, we suggest pelvic and extended paraaortic lymph node dissection rather than nodal sampling alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6649037\">",
"       'Node sampling versus resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with stage II endometrial carcinoma, we suggest performing a simple hysterectomy (extrafascial class I) (",
"      <a class=\"graphic graphic_table graphicRef57850 \" href=\"UTD.htm?13/29/13788\">",
"       table 4",
"      </a>",
"      ) with lymphadenectomy rather than radical hysterectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The exceptions to this are women with gross cervical involvement in whom performing a simple hysterectomy would cut through the tumor (all gross disease should be removed)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those in whom it is uncertain whether the primary is cervical or uterine. (See",
"      <a class=\"local\" href=\"#H16620756\">",
"       'Management of women with cervical involvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/2\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/3\">",
"      Hsieh CH, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 2002; 86:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/4\">",
"      Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 2000; 182:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/5\">",
"      Todo Y, Sakuragi N, Nishida R, et al. Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol 2003; 188:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/6\">",
"      Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 2005; 50:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/7\">",
"      Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand 2006; 85:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/8\">",
"      Kim HS, Park CY, Lee JM, et al. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study. Gynecol Oncol 2010; 118:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/9\">",
"      Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999; 212:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/10\">",
"      Beddy P, Moyle P, Kataoka M, et al. Evaluation of depth of myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2012; 262:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/11\">",
"      Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 2008; 8:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/12\">",
"      Park JY, Kim EN, Kim DY, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 2008; 108:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/13\">",
"      Horowitz NS, Dehdashti F, Herzog TJ, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004; 95:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/14\">",
"      Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol 2009; 19:1529.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer. Corpus Uteri. In: AJCC Staging Manual, 7th, Springer, New York 2010. p.403.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/16\">",
"      Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/17\">",
"      Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol 2010; 116:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/18\">",
"      Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/19\">",
"      Benedet JL. Editorial. Int J Gynaecol Obstet 2000; 70:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/20\">",
"      Mavromatis ID, Antonopoulos CN, Matsoukis IL, et al. Validity of intraoperative gross examination of myometrial invasion in patients with endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand 2012; 91:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/21\">",
"      Fanning J, Tsukada Y, Piver MS. Intraoperative frozen section diagnosis of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 1990; 37:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/22\">",
"      Quinlivan JA, Petersen RW, Nicklin JL. Accuracy of frozen section for the operative management of endometrial cancer. BJOG 2001; 108:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/23\">",
"      Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 1990; 38:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/24\">",
"      Kucera E, Kainz C, Reinthaller A, et al. Accuracy of intraoperative frozen-section diagnosis in stage I endometrial adenocarcinoma. Gynecol Obstet Invest 2000; 49:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/25\">",
"      Case AS, Rocconi RP, Straughn JM Jr, et al. A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol 2006; 108:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/26\">",
"      Egle D, Grissemann B, Zeimet AG, et al. Validation of intraoperative risk assessment on frozen section for surgical management of endometrial carcinoma. Gynecol Oncol 2008; 110:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/27\">",
"      Kwon JS, Francis JA, Qiu F, et al. When is a pathology review indicated in endometrial cancer? Obstet Gynecol 2007; 110:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/28\">",
"      Leitao MM Jr, Kehoe S, Barakat RR, et al. Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2008; 111:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/29\">",
"      Kumar S, Medeiros F, Dowdy SC, et al. A prospective assessment of the reliability of frozen section to direct intraoperative decision making in endometrial cancer. Gynecol Oncol 2012; 127:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/30\">",
"      Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/31\">",
"      Boronow RC, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 1984; 63:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/32\">",
"      ASTEC study group, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/33\">",
"      Todo Y, Yamamoto R, Minobe S, et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol 2010; 119:60.",
"     </a>",
"    </li>",
"    <li>",
"     https://gogmember.gog.org/manuals/pdf/surgman.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/35\">",
"      Dowdy SC, Aletti G, Cliby WA, et al. Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol 2008; 111:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/36\">",
"      Aalders JG, Thomas G. Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. Gynecol Oncol 2007; 104:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/37\">",
"      Homesley HD, Kadar N, Barrett RJ, Lentz SS. Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. Am J Obstet Gynecol 1992; 167:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/38\">",
"      Franchi M, Ghezzi F, Riva C, et al. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol 2001; 78:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/39\">",
"      Russell AH. Forwards through the rear-view mirror. Gynecol Oncol 2009; 115:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/40\">",
"      Larson DM, Johnson KK. Pelvic and para-aortic lymphadenectomy for surgical staging of high-risk endometrioid adenocarcinoma of the endometrium. Gynecol Oncol 1993; 51:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/41\">",
"      Yokoyama Y, Maruyama H, Sato S, Saito Y. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 1997; 64:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/42\">",
"      McMeekin DS, Lashbrook D, Gold M, et al. Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol 2001; 82:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/43\">",
"      Yaegashi N, Ito K, Niikura H. Lymphadenectomy for endometrial cancer: is paraaortic lymphadenectomy necessary? Int J Clin Oncol 2007; 12:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/44\">",
"      Abu-Rustum NR, Gomez JD, Alektiar KM, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 2009; 115:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/45\">",
"      Todo Y, Kato H, Kaneuchi M, et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010; 375:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/46\">",
"      Abu-Rustum NR, Chi DS, Leitao M, et al. What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma? Gynecol Oncol 2008; 111:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/47\">",
"      Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995; 56:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/48\">",
"      Chan JK, Cheung MK, Huh WK, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006; 107:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/49\">",
"      Mariani A, Webb MJ, Keeney GL, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000; 182:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/50\">",
"      Chan JK, Wu H, Cheung MK, et al. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 2007; 106:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/51\">",
"      Pierga JY, Dieras V, Paraiso D, et al. Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study. Gynecol Oncol 1996; 60:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/52\">",
"      Grigsby PW, Perez CA, Kuten A, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 1992; 22:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/53\">",
"      Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/54\">",
"      Abu-Rustum NR, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/55\">",
"      Frumovitz M, Singh DK, Meyer L, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 2004; 95:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/56\">",
"      Ben-Shachar I, Pavelka J, Cohn DE, et al. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 2005; 105:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/57\">",
"      Roland PY, Kelly FJ, Kulwicki CY, et al. The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment. Gynecol Oncol 2004; 93:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/58\">",
"      Gershenson DM. Why American women are not receiving state-of-the-art gynecologic cancer care. Cancer J 2001; 7:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/59\">",
"      Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol 2000; 78:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/60\">",
"      Frumovitz M, Levenback CF. Is lymphatic mapping in uterine cancer feasible? Ann Surg Oncol 2008; 15:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/61\">",
"      Kang S, Yoo HJ, Hwang JH, et al. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol 2011; 123:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/62\">",
"      Robison K, Holman LL, Moore RG. Update on sentinel lymph node evaluation in gynecologic malignancies. Curr Opin Obstet Gynecol 2011; 23:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/63\">",
"      Palomba S, Falbo A, Mocciaro R, et al. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol 2009; 112:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/64\">",
"      Tozzi R, Malur S, Koehler C, Schneider A. Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy? Gynecol Oncol 2005; 97:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/65\">",
"      Sonoda Y, Zerbe M, Smith A, et al. High incidence of positive peritoneal cytology in low-risk endometrial cancer treated by laparoscopically assisted vaginal hysterectomy. Gynecol Oncol 2001; 80:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/66\">",
"      Niikura H, Okamura C, Utsunomiya H, et al. Sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol 2004; 92:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/67\">",
"      Mais V, Peiretti M, Gargiulo T, et al. Intraoperative sentinel lymph node detection by vital dye through laparoscopy or laparotomy in early endometrial cancer. J Surg Oncol 2010; 101:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/68\">",
"      Disaia PJ. Predicting parametrial involvement in endometrial cancer: is this the end for radical hysterectomies in stage II endometrial cancers? Obstet Gynecol 2010; 116:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/69\">",
"      Watanabe Y, Satou T, Nakai H, et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol 2010; 116:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/70\">",
"      Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010; 118:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/71\">",
"      Mourits MJ, Bijen CB, Arts HJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 2010; 11:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/72\">",
"      Janda M, Gebski V, Brand A, et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncol 2010; 11:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/73\">",
"      de la Orden SG, Reza MM, Blasco JA, et al. Laparoscopic hysterectomy in the treatment of endometrial cancer: a systematic review. J Minim Invasive Gynecol 2008; 15:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/74\">",
"      Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009; 27:5331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/75\">",
"      Fanning J, Hossler C. Laparoscopic conversion rate for uterine cancer surgical staging. Obstet Gynecol 2010; 116:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/76\">",
"      Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008; 109:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/77\">",
"      Gaia G, Holloway RW, Santoro L, et al. Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol 2010; 116:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/78\">",
"      Fader AN, Cohen S, Escobar PF, Gunderson C. Laparoendoscopic single-site surgery in gynecology. Curr Opin Obstet Gynecol 2010; 22:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/79\">",
"      Escobar PF, Fader AN, Rasool N, Espalliat LR. Single-port laparoscopic pelvic and para-aortic lymph node sampling or lymphadenectomy: development of a technique and instrumentation. Int J Gynecol Cancer 2010; 20:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/80\">",
"      Susini T, Massi G, Amunni G, et al. Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. Gynecol Oncol 2005; 96:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/81\">",
"      Chan JK, Lin YG, Monk BJ, et al. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 2001; 97:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/82\">",
"      Resnick K, Straughn JM Jr, Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol 2009; 114:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/83\">",
"      Backes FJ, Leon ME, Ivanov I, et al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecol Oncol 2009; 114:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/84\">",
"      Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 2009; 114:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/85\">",
"      Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003; 100:5908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/86\">",
"      Stefansson I, Akslen LA, MacDonald N, et al. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clin Cancer Res 2002; 8:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/87\">",
"      Chadwick RB, Pyatt RE, Niemann TH, et al. Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma. J Med Genet 2001; 38:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/88\">",
"      Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006; 24:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/89\">",
"      Dunlop MG, Farrington SM, Nicholl I, et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer 2000; 83:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/90\">",
"      Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 2001; 83:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/91\">",
"      Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 2004; 94:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/92\">",
"      Walsh C, Holschneider C, Hoang Y, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 2005; 106:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/93\">",
"      Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 1985; 16:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/94\">",
"      In memoriam William Henry Daines Trubshaw 1908-1971. S Afr J Surg 1971; 9:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/95\">",
"      Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/23/18810/abstract/96\">",
"      Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1:S105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3251 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-50DD9E1A11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18810=[""].join("\n");
var outline_f18_23_18810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Assessment for hereditary cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STAGING AND PRIMARY SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgical staging overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intraoperative gross inspection and frozen section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lymph node evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6650537\">",
"      - Prevalence of and risk factors for nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6649498\">",
"      - Anatomy of pelvic and paraaortic nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6650587\">",
"      - Controversies in lymph node assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6650486\">",
"      Assessment of paraaortic nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6649037\">",
"      Node sampling versus resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sentinel node biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16620756\">",
"      Management of women with cervical involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Robot-assisted or single port laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vaginal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Testing of tumor specimen for mismatch repair deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SPECIAL CLINICAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Synchronous ovarian and endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Inoperable patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fertility preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6520494\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3251|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/50/27425\" title=\"figure 1\">",
"      Lymph nodes female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/44/38596\" title=\"figure 2\">",
"      Female pelvic lymphadenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3251|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/7/10358\" title=\"picture 1\">",
"      Adenocarcinoma of endometrium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3251|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43549\" title=\"table 1\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/7/7291\" title=\"table 2\">",
"      Uterine carcinoma grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/26/15788\" title=\"table 3\">",
"      LN metastases in endometrial CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/29/13788\" title=\"table 4\">",
"      Types of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/39/31356\" title=\"table 5\">",
"      Uterine cancer survival",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=related_link\">",
"      Adjuvant treatment of intermediate-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=related_link\">",
"      Approach to adjuvant treatment of endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=related_link\">",
"      Cellulitis following pelvic lymph node dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9029?source=related_link\">",
"      Laparoendoscopic single-site (single port) surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=related_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4455?source=related_link\">",
"      Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=related_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23747?source=related_link\">",
"      Patient information: Uterine cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24201?source=related_link\">",
"      Preoperative management of patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=related_link\">",
"      Robot-assisted laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15257?source=related_link\">",
"      Treatment and prognosis of uterine leiomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=related_link\">",
"      Treatment of locally advanced, recurrent, or metastatic endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=related_link\">",
"      Treatment of low-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_23_18811="Methoxsalen doses";
var content_f18_23_18811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dose schedule for methoxsalen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Patient weight",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Methoxsalen dose (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        (lb)",
"       </td>",
"       <td class=\"subtitle2\">",
"        (kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &lt;66",
"       </td>",
"       <td class=\"centered\">",
"        &lt;30",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        66-143",
"       </td>",
"       <td class=\"centered\">",
"        30-65",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        144-200",
"       </td>",
"       <td class=\"centered\">",
"        65-90",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &gt;200",
"       </td>",
"       <td class=\"centered\">",
"        &gt;90",
"       </td>",
"       <td class=\"centered\">",
"        40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of: Informa Healthcare, from Phototherapy and Photochemotherapy of Skin Disease, Morison WL, 3rd ed, New York 2005; permission conveyed through Copyright Clearance Center, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18811=[""].join("\n");
var outline_f18_23_18811=null;
var title_f18_23_18812="Higher cortical function in children";
var content_f18_23_18812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of higher cortical function in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evidence of normal cortical function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        6 to 12 months",
"       </td>",
"       <td>",
"        Awareness of surroundings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interaction with examiner (social smile, inquisitiveness, habituation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cooing and gurgling, sometimes making of nonspecific \"mama\" and \"dada\" sounds",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        12 to 20 months",
"       </td>",
"       <td>",
"        Six to eight word vocabulary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comprehends one-step commands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Points to two or three body parts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        24 months",
"       </td>",
"       <td>",
"        Names two or three body parts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uses phrases and simple sentences",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        24 to 36 months",
"       </td>",
"       <td>",
"        Concept of self (referring to self as \"I\", knowledge of name and age)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        36 months",
"       </td>",
"       <td>",
"        Counts three objects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Understands prepositional concepts (eg, \"over\" and \"under\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asks questions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Names three colors",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        48 months",
"       </td>",
"       <td>",
"        Copies a square and a cross",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        5 or 6 years",
"       </td>",
"       <td>",
"        Spells monosyllabic words",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Counts to 10",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        6 years",
"       </td>",
"       <td>",
"        Copies a triangle",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        6 or 7 years",
"       </td>",
"       <td>",
"        Does simple addition and subtraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reads polysyllabic words",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        7 years",
"       </td>",
"       <td>",
"        Copies a diamond",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18812=[""].join("\n");
var outline_f18_23_18812=null;
var title_f18_23_18813="Organophosphate and carbamate poisoning - Rapid overview";
var content_f18_23_18813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Organophosphate and carbamate poisoning: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Acute toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generally manifests in minutes to hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Evidence of cholinergic excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        SLUDGE = Salivation, Lacrimation, Urination, Defecation, Gastric Emptying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        BBB = Bradycardia, Bronchorrhea, Bronchospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory insufficiency can result from muscle weakness, decreased central drive, increased secretions, and bronchospasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Occurs 24-96 hours after exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bulbar, respiratory, and proximal muscle weakness are prominent features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generally resolves in 1-3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Organophosphorous Agent-Induced Delayed Peripheral Neuropathy (OPIDN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Usually occurs several weeks after exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Primarily motor involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        May resolve spontaneously, but can result in permanent neurologic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation of acute toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Atropine challenge if diagnosis is in doubt (1 mg IV in adults, 0.01 to 0.02 mg/kg in children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Absence of anticholinergic signs (tachycardia, mydriasis, decreased bowel sounds, dry skin) strongly suggests poisoning with organophosphate or carbamate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Draw blood sample for measurement of RBC acetylcholinesterase activity to confirm diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment of acute toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deliver 100 percent oxygen via facemask; early intubation often required; avoid succinylcholine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Decontamination",
"        </strong>",
"        if ingestion within 1 hour give single dose activated charcoal, adult 50 g (1 g/kg in children) unless airway not protected or other contraindication. Aggressive dermal and ocular irrigation as needed. Bag/discard clothing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Atropine",
"        </strong>",
"        2 to 5 mg IV/IM/IO bolus (0.05 mg/kg IV in children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Escalate (double) dose every 3-5 minutes until bronchial secretions and wheezing stop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        TACHYCARDIA AND MYDRIASIS ARE NOT CONTRAINDICATIONS TO ATROPINE USE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hundreds of milligrams may be needed over several days in severe poisonings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inhaled ipratropium 0.5 mg with parenteral atropine may be helpful for bronchospasm; may repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Pralidoxime",
"        </strong>",
"        (2-PAM) 2 g (25 mg/kg in children) IV over 30 minutes; may repeat after 30 minutes or give continuous infusion if severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Continuous infusion at 8 mg/kg/hour in adults (10 mg/kg/hour in children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If no IV access, give pralidoxime 600 mg IM (15 mg/kg in children &lt;40 kg). Rapidly repeat as needed to total of 1800 mg or 45 mg/kg in children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pralidoxime is given with atropine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Benzodiazepine therapy",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diazepam 10 mg IV (0.1 to 0.2 mg/kg in children), repeat as necessary if seizures occur. Do not give phenytoin.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18813=[""].join("\n");
var outline_f18_23_18813=null;
var title_f18_23_18814="Empiric oral rx pneumonia child";
var content_f18_23_18814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial oral empiric antibiotics for outpatient treatment of pediatric community-acquired pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Empiric regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        1 to 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial (not",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        <strong>",
"         Infants &lt;3 to 6 months of age with suspected bacterial pneumonia should be hospitalized",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlamydia trachomatis",
"       </td>",
"       <td>",
"        See UpToDate topic&nbsp;on",
"        <em>",
"         Chlamydia trachomatis",
"        </em>",
"        infections in the newborn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        6 months to 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"12\">",
"        Typical bacterial*",
"       </td>",
"       <td>",
"        Amoxicillin",
"        <sup>",
"         &bull;",
"        </sup>",
"        90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin-clavulanate 90 mg/kg per day of the amoxicillin component in 2 or 3 divided doses (MAX 4 g/day amoxicillin component),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         For patients with non type 1 hypersensitivity to penicillins:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         For patients with type 1 hypersensitivity to penicillins:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Erythromycin 30 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethylsuccinate),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Azithromycin 10 mg/kg on day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on day 1 and 250 mg thereafter),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         In communities with a high rate of pneumococcal resistance to penicillin:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Linezolid 30 mg/kg per day in 3 divided doses (MAX 1800 mg/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Levofloxacin 16 to 20 mg/kg per day in 2 divided doses (MAX 750 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        &ge;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"7\">",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"        or",
"        <em>",
"         Chlamydophila pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Erythromycin 40 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethylsuccinate),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin 10 mg/kg on day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on day 1 and 250 mg thereafter),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxycycline",
"        <sup>",
"         &Delta;",
"        </sup>",
"        4 mg/kg per day in 2 divided doses (MAX 200 mg/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         For skeletally mature patients:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Levofloxacin",
"        <sup>",
"         &loz;",
"        </sup>",
"        8 to 10 mg/kg once daily for children 5 to 16 years (MAX 500 mg/day); 500 mg once per day for children for children &ge;16 years,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Moxifloxacin",
"        <sup>",
"         &loz;",
"        </sup>",
"        400 mg once per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"12\">",
"        Typical bacterial*",
"       </td>",
"       <td>",
"        Amoxicillin",
"        <sup>",
"         &bull;",
"        </sup>",
"        90 mg/kg per day in 2 or 3 divided doses (MAX 4 g/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         For patients with non type 1 hypersensitivity to penicillins:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Cefdinir 14 mg/kg per day in 2 divided doses (MAX 600 mg/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Cefpodoxime 10 mg/kg per day in 2 divided doses (MAX 400 mg/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         For patients with type 1 hypersensitivity to penicillins:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Clindamycin 30 to 40 mg/kg per day in 3 or 4 divided doses (MAX 1.8 g/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Erythromycin 40 to 50 mg/kg per day in 4 divided doses (MAX 2 g/day as base, 3.2 g/day as ethyl succinate),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Azithromycin 10 mg/kg on day 1 followed by 5 mg/kg daily for 4 more days (MAX 500 mg on day 1 and 250 mg thereafter),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Clarithromycin 15 mg/kg per day in 2 divided doses (MAX 1 g/day),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         In communities with a high rate of pneumococcal resistance to penicillin:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Linezolid 30 mg/kg per day divided in 3 doses (MAX 1800 mg/day) for children &lt;12 years; 20 mg/kg per day divided in 2 doses (MAX 1200 mg/day) for children &ge;12 years,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Levofloxacin 8 to 10 mg/kg once daily for children 5 to 16 years (MAX 750 mg/day); 750 mg once daily for children &ge;16 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Aspiration pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Community-acquired",
"       </td>",
"       <td>",
"        Amoxicillin-clavulanate 40 to 50 mg/kg per day in 2 or 3 divided doses (MAX 1750 mg/day amoxicillin component),",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         For patients with type 1 hypersensitivity to beta-lactam antibiotics:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Clindamycin 30 to 40 mg/kg per day, divided in 3 or 4 doses (MAX 1.8 g/day)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CAP: community-acquired pneumonia; MAX: maximum.",
"     <br/>",
"     * For the infant or child who is suspected to have bacterial CAP and is unable to tolerate liquids at the time of presentation, a single initial dose of ceftriaxone (50 to 75 mg/kg) may be administered intramuscularly or intravenously before starting oral antibiotics.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Preferred agent.",
"     <br/>",
"     &Delta; Should be used with caution in patients under the age of eight years.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Also covers typical bacterial pathogens.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.",
"      </li>",
"      <li>",
"       Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.",
"      </li>",
"      <li>",
"       American Academy of Pediatrics. Antibacterial drugs for pediatric patients beyond the newborn period. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed. American Academy of Pediatrics, Elk Grove Village, IL 2009. p.747.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18814=[""].join("\n");
var outline_f18_23_18814=null;
var title_f18_23_18815="Beard distribution hemangioma";
var content_f18_23_18815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemangioma in the beard distribution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The \"beard\" (Segment 3) distribution includes the preauricular skin, chin, anterior neck, and/or lower lip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_23_18815=[""].join("\n");
var outline_f18_23_18815=null;
